Podcasts about AstraZeneca

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest breakthroughs and trends shaping the landscape of medicine and treatment. In the realm of weight management and metabolic disorders, significant advancements are underway. Roche and Zealand Pharma have moved Petrelintide, an amylin analog, into a Phase 3 clinical trial after a promising Phase 2 showing a nearly 10% weight loss in participants. This development highlights an increasing focus on protein-based therapies for metabolic conditions, offering new hope for tackling obesity—a major global health challenge. Similarly, Eli Lilly's Retatrutide has made headlines with its Phase 3 trial results, demonstrating a remarkable 25% body weight reduction in obese patients with type 2 diabetes. This triple agonist targets multiple receptors, marking a novel approach in metabolic therapeutics that could transform obesity and diabetes management by targeting key pathways regulating energy balance and glucose levels. In oncology, Pierre Fabre and Atara Biotherapeutics have resubmitted their Biologics License Application for Ebvallo (tabelecleucel) to the FDA. This follows successful Phase 3 trials targeting Epstein-Barr virus-positive post-transplant lymphoproliferative disease, a severe complication post-transplantation. If approved, tabelecleucel could provide a critical allogeneic T-cell therapy option for these patients, underscoring the evolution of cell-based therapies in cancer treatment. Regulatory news is also making waves with Segetis Therapeutics receiving FDA approval for Emcitate (tiratricol), designed to treat monocarboxylate transporter 8 deficiency. This approval is particularly significant as it marks the first U.S. treatment for this rare pediatric thyroid hormone disorder, showcasing the industry's dedication to addressing rare diseases' unmet needs. Meanwhile, artificial intelligence continues to reshape drug discovery and development processes. Collaborations such as GSK's with Wave Life Sciences on hepatic siRNA programs and Novartis Biomedical Research's partnership with CAS aim to enhance drug discovery workflows through advanced data analytics and machine learning models. In clinical trial news, Highlight Therapeutics reported successful Phase 2 results for BO-112 in high-risk head and neck basal cell carcinoma. The immunotherapy showed efficacy as an intralesional therapy, providing new hope for patients at high risk of cancer recurrence or progression. Furthermore, Amgen's Daxdilimab demonstrated positive outcomes in a Phase 2 trial for discoid lupus erythematosus by significantly reducing disease severity, highlighting interest in targeted therapies for autoimmune conditions. Connect Biopharma's Rademikibart has shown promise in reducing exacerbations of chronic obstructive pulmonary disease during its Phase 2 trial. As an IL-4/IL-13 inhibitor, it stands as a potential competitor to existing treatments like Dupixent, potentially reshaping therapeutic strategies in respiratory diseases. These advancements reflect broader trends within the pharmaceutical industry towards personalized medicine, innovative drug mechanisms, and strategic partnerships leveraging AI and advanced analytics. As these therapies progress through clinical trials and regulatory pathways, they hold promise for enhancing patient care and expanding treatment options across various disease areas. In related regulatory developments, the European Commission has revoked marketing authorization for Hansoh Pharma's Aumseqa following a legal challenge by AstraZeneca. This decision underscores the competitive nature of oncology and highlights the importance of patent disputes and regulatory compliance in maintaining market presence. On the corporate strategy front, PhRMA has appointed former House Majority Leader Eric Cantor as its CEO. This move indicates PhRMA's focus on navigating complex regulatory environments crucial for shaping healthcare policies impacting drug development and pricing. The White House is also taking steps to address global supply chain vulnerabilities by boosting domestic production of essential medicines—a strategy aimed at enhancing national security while ensuring a steady supply of critical drugs. In industry funding news, NorthStar Medical Technologies secured $185 million to advance radiopharmaceutical isotope production. With commercial-scale manufacturing of Actinium-225 completed earlier this year, NorthStar is set to significantly increase capacity by year-end—reflecting growing demand within precision medicine. In space-based innovations, Varda Space Industries raised $251 million to fuel pioneering drug manufacturing using reusable rockets in Earth's low orbit—potentially revolutionizing drug production by utilizing microgravity environments. Finally, recent developments highlight challenges within the industry as well. Companies like Novo Nordisk and BioMarin face layoffs amid evolving market demands. Meanwhile, Enanta Pharmaceuticals downsizes amid forthcoming antiviral readouts—a reflection of broader strategic pivots required to remain competitive. These developments underscore an era where scientific breakthroughs are rapidly transforming drug development paradigms. As companies navigate intellectual property challenges and strategic collaborations continue to drive innovation aimed at addressing diverse unmet medical needs across therapeutic areas, stakeholders are likely to witness continued growth and transformation in drug development and delivery paradigms worldwide. Thank you for joining us on Pharma Daily—your go-to source for insights into the ever-evolving pharmaceutical and biotech industries. Stay tuned for more updates as we continue to explore groundbreaking advancements shaping the future of medicine.Support the show

À quelques jours du Mondial de l'auto 2026, Cyril Attias reçoit Cécilia Taïeb, directrice de la communication mondiale de SEAT et Cupra. Elle vient de la pharma et de l'oncologie (AstraZeneca), et a rejoint Cupra en 2021 pour transformer une marque qui n'avait alors que deux ans.Elle raconte comment Cupra s'est construite en cassant les codes du secteur automobile : photos sombres plutôt que « trois quarts » réglementaires, couleurs « earthy » (le rouge a été supprimé de la gamme), lancements sans bâche, campagnes qu'on ne reconnaît pas comme des pubs de voiture. Le lancement de la CUPRA Raval a été marqué par une série de concerts gratuits organisés simultanément dans six villes, dans le cadre de la campagne « École de la rue ».Côté influence, sa méthode est claire : environ vingt créateurs de contenu internes, une sélection qui place la passion de la marque et la crédibilité avant les followers, et l'engagement plutôt que l'audience. Elle explique pourquoi Cupra refuse les créateurs qui n'ont pas le permis de conduire.Épisode disponible en vidéo sur YouTube — retrouvez les interviews complètes en format vidéo pour une expérience encore plus immersive. → YouTubeVous appréciez le podcast ? Laissez une note 5 étoiles sur Apple Podcasts ou Spotify — c'est gratuit, ça prend 10 secondes, et c'est le meilleur moyen d'aider d'autres professionnels du marketing à le découvrir.→ YouTube - Apple Podcasts - Spotify - Deezer - Toutes plateformes (Smartlink) ·Suivez ADMS.PARIS I Globe Groupe sur LinkedIn et connectez-vous directement à Cyril Attias (LinkedIn) pour échanger sur le marketing, l'influence et les stratégies de marque.Abonnez-vous à notre compte Instagram Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Jessica talks with Hugo Pérez, an Emmy-winning storyteller, strategist, and founder of Local Boy Co., a creative consultancy and studio helping organizations find their message, sharpen it, and make it matter. A full-stack marketer with more than two decades of experience, he has led transformative work across advertising, higher education, startups, nonprofits, and brands—including Starbucks, Taco Bell, Allstate, MTV, Mars, AstraZeneca, and AT&T. Most recently, he served as CMO of a global plant-based food brand. Hugo is a speaker, mentor, educator, and author of Sparked: Rebellious Leadership Beyond the Ordinary. Across every platform, his work reflects one conviction: bold and honest stories remain among the most powerful tools we have to move people and ideas forward.Learn more about Hugo and his work at localboycreative.com. ~About The Ampersand Manifesto:What happens when you refuse to choose just one path? On The Ampersand Manifesto, host Jessica Wan sits down with “the most interesting people at the dinner party” – those who have made their mark in two or more seemingly different worlds. Through candid conversations, we explore what it takes to navigate multiple callings, find the connection points between them, and redefine success on our own terms. Together, we're co-creating The Ampersand Manifesto: principles for leading a multi-passionate life.~About your host, Jessica Wan:Executive Coach | Classical Singer | Former Marketing Leader & Tech ExecutiveJessica helps founders and leaders make the invisible visible. With 20+ years of experience scaling brands like Apple, Smule, and the San Francisco Opera, and as an ICF-certified executive coach, she provides the clarity and strategy needed to lead bravely and find fulfillment in a multi-passionate life.Work with Jessica: Book a Free Intro CallJoin The Cohort: An Ampersand Community for Dual-Career ProfessionalsFollow the Journey: @ampersandmanifestoConnect: Jessica's LinkedInListen: Singing Excerpts~CreditsCo-produced and hosted by ⁠Jessica Wan⁠Co-produced, edited, sound design, and original music by ⁠Carlos Schmitt

Unser gemeinsamer Podcast mit Christian Röhl von Asset Class & Scalable Capital: https://www.youtube.com/watch?v=pEZzKuIhSSU&t=1759s Oura cancelt IPO. Anthropic leakt Börsendokumente, wächst verrückt, verbrennt verrückt. AMD kauft KI-Startup für 8 Mrd. $. Novo Nordisk lizensiert Abnehmpille. FICO verliert nach Monopol-Aus. Carnival bucht Rekorde. Summit & AstraZeneca machen Deal. Brookfield Corp (WKN: A3D3EV) hat 19% Rendite pro Jahr über 30 Jahre geliefert. Jetzt 20% gefallen. Das Management sieht den fairen Wert bei fast dem Doppelten. Zu Recht? Aritzia (WKN: A2AS0Y): 570% seit IPO, mehr wert als GAP, Levis oder Puma. 140 Läden, keine Spiegel in Umkleiden und Style-Berater statt Verkäufer. Kanadas Mode-Maschine will jetzt die USA erobern. Diesen Podcast vom 30.09.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative developments across the pharmaceutical and biotech sectors, highlighting strategic investments, innovative therapies, and regulatory milestones. AstraZeneca's recent $2 billion investment in Summit Therapeutics is a testament to the industry's focus on cutting-edge oncology solutions. This substantial funding aims to advance the development of ivonescimab, a PD-1xVEGF bispecific antibody, in conjunction with antibody-drug conjugates. This strategic move underscores the potential of combining different therapeutic modalities to target complex cancer pathways, particularly in gastrointestinal malignancies. By leveraging dual-targeting capabilities, these therapies promise enhanced efficacy, marking a significant step forward in cancer treatment paradigms. Meanwhile, Novo Nordisk is making strides in metabolic disease management through its partnership with Hengrui Pharma. This collaboration to develop a weekly oral GLP-1R/GIPR dual agonist for obesity underscores the growing emphasis on innovative metabolic therapies. The upfront payment of $300 million, with additional milestone payments potentially reaching $2.6 billion, reflects the high stakes involved in addressing obesity—a global health challenge. This approach could revolutionize current treatment standards by improving patient compliance and outcomes through targeted small molecule interventions. On the manufacturing front, Genentech's $750 million expansion of its Hillsboro facility highlights the increasing demand for biopharmaceuticals. This investment is poised to double the facility's size by 2031, supporting new drug approvals in oncology, neurology, and immunology. Enhanced production capacity is crucial for meeting the intricate requirements of biologics and personalized medicine, ensuring that breakthrough treatments reach patients more effectively. In the realm of antibody research, Ginkgo Bioworks, AbbVie, and Takeda have joined forces to form the Antibody Developability Consortium. By creating a standardized dataset for antibody development using artificial intelligence and machine learning, this initiative aims to streamline the discovery and manufacturability of therapeutic antibodies. The collaboration seeks to overcome existing challenges in antibody drug development, potentially expediting time-to-market for new therapies. In neurology, AC Immune's Phase 2 trial of ACI-7104 has shown promising results in early-stage Parkinson's disease by meeting all primary endpoints and demonstrating complete immunogenicity. This active immunotherapy targeting alpha-synuclein presents hope for modifying disease progression rather than merely alleviating symptoms. Such advancements highlight the potential of vaccination strategies in addressing neurodegenerative diseases. Roche is also embracing innovation by planning autonomous AI labs for drug R&D. These labs are expected to accelerate clinical candidate development significantly, reducing costs while improving success rates in bringing new drugs to market. This initiative exemplifies how AI-driven drug discovery is reshaping research methodologies. Despite these advancements, challenges persist within the industry. UniQure's gene therapy for Huntington's disease showed diminished effectiveness over four years in Phase 1/2 trials, illustrating the complexities inherent in developing neurological disorder treatments. Additionally, BioNTech's closure of three sites in Germany resulting in substantial job cuts highlights broader economic pressures despite its success with mRNA vaccines. Regulatory developments are crucial as well. The FDA's approval of Roche's Gazyva for idiopathic nephrotic syndrome marks a pivotal advancement as it becomes the first treatment option for this condition in 70 years. This approval not only provides hope for patients but also sets a precedent for future research into autoimmune diseases. In contrast to these successes, Roche decided to discontinue its muscle-sparing obesity antibody following disappointing phase 2 results. Such outcomes emphasize the importance of interim analyses and adaptive strategies in drug development. Overall, these updates underscore a dynamic period characterized by strategic investments, technological innovation, and collaborative efforts aimed at addressing some of healthcare's most pressing challenges. The integration of cutting-edge technologies such as AI and novel therapeutic modalities continues to drive progress towards more effective and personalized patient care solutions. As we wrap up today's episode of Pharma Daily, it's clear that while opportunities abound within the industry through scientific breakthroughs and strategic collaborations, challenges remain that require careful navigation. Companies that balance innovation with rigorous clinical evaluation will be at the forefront of delivering transformative healthcare solutions globally. Thank you for tuning into Pharma Daily; stay informed with us as we continue to track these evolving trends shaping the future of pharmaceuticals and biotech.Support the show

The biggest night in medical marketing returns on Thursday.The 2026 MM+M Awards will take place at Cipriani Wall Street on October 1, and honestly, it will probably be the biggest night in the 60-year history of MM+M when it's all said and done.We're set to bestow honors for the top ad campaigns and educational initiatives, for the lead agencies by category as well as for a pair of leaders who have spent decades of their respective careers pushing medical marketing forward.The centerpiece of the night will also be remarks delivered by Platinum Award honoree Gabrielle Union, a partner of Bayer, Knix and Clearblue alongside her out-loud advocacy about living with adenomyosis, menopausal, perimenopausal and mental health challenges. There's so much exciting stuff in the works and executive editor Jack O'Brien is joined by this week's guest, 2026 MM+M Awards jury chair Jen Clifford of AstraZeneca. Jen is here not only to preview our big night of glitz and glam, but also to discuss overseeing the judging process for the awards and offer best practices for how to most effectively nominate work for the 2027 MM+M Awards. Following that conversation, I'm joined by pharma editor Lecia Bushak and reporter Bella Czajkowski to talk about the throughline from a few pharma ads of the post-Untitled Letter era, featuring appearances by Ardelyx, Johnson & Johnson, AstraZeneca and Eli Lilly. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab's late-stage development; uniQure crashes after four-year data from its Huntington's disease gene therapy failed to impress; Kyverna Therapeutics brings new light to a struggling CAR T space in autoimmune disease.

A.M. Edition for Sept. 29. OpenAI is scrapping its new model over safety concerns in one of the clearest signs yet that agent misbehavior could stymie the industry's rapid progression. Oxford Analytica's Tatia Bolkvadze explains what this means for AI revenues, ahead of Anthropic's much-anticipated IPO. Plus, an exclusive look at who's in line to be Goldman's next CEO. And WSJ's Nick Kostov reports on how luxury brands are targeting the ultra-wealthy as well as your average Joe, at Paris fashion week. Daniel Bach hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This week on Sinica, I sit down with Dr. Ruby Wang, whose new book, China Cure: The Rise of a Biotech, AI Medicine and Global Health Superpower (Agenda Publishing, out October 31, with a foreword by Kerry Brown), is the explanation general readers have been missing for one of the most consequential and least understood transformations in China today. Ruby is a rare creature in this space: a practicing physician in Britain's NHS, trained in surgery, who worked London's hospital wards through the first wave of COVID; the former head of the UK government's health engagement in China at the British Embassy in Beijing; a former health adviser within the UN system; a onetime medical adviser at AliHealth in Hangzhou; and a Schwarzman Scholar. She now runs the strategy consultancy Lintris Health and writes the excellent China Health Pulse newsletter and podcast, both of which I recommend to anyone trying to follow this space.Anyone who spent time in a Chinese hospital in the late ‘80s or ‘90s — the pre-dawn queues, the ticket scalpers, the cashier's window at every step, the IV drips for a head cold — will find the arc of this book hard to believe. Within living memory, China sent barefoot doctors into the countryside with herbal remedies and antibiotics in army-green satchels; last year, Chinese companies signed something like 186 out-licensing deals worth a disclosed $137 billion, roughly half the global total and close to ten times the 2021 figure, with Pfizer, Bristol-Myers Squibb, AstraZeneca, GSK, and Eli Lilly all buying. Since Ruby gave a terrific interview to my friend Kyle Chan on his High Capacity podcast this spring on the apps, data flows, and clinical AI, I deliberately steered elsewhere: to her family — a deckhand grandfather, a father's crooked splint, a grandmother's transnational hunt for Gleevec — to the four reinforcing conditions she argues made the transformation possible, to the “China is fast because China is loose” shortcut and what's actually behind the speed, to BIOSECURE and its successors, to the AI doctor avatars now fielding millions of inquiries a year, and to the burnout and violence that still bedevil the lives of Chinese clinicians.10:31 – Two family stories from 1970s Zhejiang: a deckhand grandfather and a barefoot doctor's crooked splint15:57 – Four reinforcing conditions, part one: demographic pressure and crisis as catalyst (SARS, melamine, fake vaccines)23:42 – The long view: Healthy China 2030 and why China's health ministers are technocrats27:54 – The cultural inheritance: who signs the consent form, and China's health codes vs. Britain's billion-pound app35:26 – Grandma and Gleevec: a family's transnational hunt for a drug in 200340:17 – The reversal: hǎiguī, copycats to first-in-class, and the tenfold surge in out-licensing42:35 – Is China fast because China is loose? Where China leads (oncology, GLP-1s) and where it lags50:22 – BIOSECURE, COINS, and BINSA: who loses when politics meets pharma55:37 – Digital health in three systems, Ant Afu's AI doctor avatars, and whether the silver generation can keep up1:08:44 – “A lifetime of eating bitterness”: Dr. Wang of Guangzhou, burnout, and yī nàoPaying It ForwardYanzhong Huang, senior fellow for global health at the Council on Foreign Relations and professor at Seton Hall — the go-to voice on the geopolitics of China and health, and Ruby's first port of call.Afra Wang, writer of the Concurrent newsletter — Ruby admires how she reads the cultural currents beneath technology, and finds it endlessly useful to take those insights to the health-tech angle.Olivia Plotnick, Shanghai-based founder of Wai Social — on-the-ground work on branding and consumer behavior across some 30 lower-tier Chinese cities, including health and wellness.RecommendationsRuby: Deep China: The Moral Life of the Person, edited by Arthur Kleinman with Yunxiang Yan, Jing Jun, Sing Lee, and others — what being sick reveals about society and culture in China: psychiatry, caregiving, and how patients and families have changed as the country has. Kleinman's The Soul of Care is also worth your time.Kaiser: Augustus by John Williams — the third of his novels I've recommended on the show, and the National Book Award winner: an epistolary novel of imperial Rome told through a crazy quilt of letters and fragments from family, friends like Agrippa, and poets like Virgil and Horace, each given a completely distinct voice. Quiet campus novel, anti-Western, imperial Rome — the range, and the restraint, are astonishing.Also: Ezra Klein's conversation with Carnegie's Matt Sheehan — a masterclass in clarity on AI safety and the U.S.-China relationship, and the best thing to listen to in the wake of Dario Amodei's “Pacing the Frontier” essay.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

AstraZeneca, multinazionale biofarmaceutica anglo-svedese, ha annunciato un piano di investimenti da oltre 66 milioni di euro in Italia nei prossimi tre anni per la ricerca clinica e l'innovazione, nel corso di una conferenza stampa alla presenza del Ministero delle Imprese e del Made in Italy (Mimit) alla presenza del ministro Adolfo Urso. ll programma, che vede un cofinanziamento di 20 milioni del Fondo per la ricerca e lo sviluppo industriale e biomedico del Mimit, spazia dalla ricerca clinica alla digital health e coinvolgerà oltre 200 centri sul territorio nazionale. Ne parliamo con Claudio Longo, Country President di Astrazeneca.Shein crolla dell'11,7% a Hong Kong dopo il calo degli utili Le azioni di Shein sono crollate dell'11,7% alla Borsa di Hong Kong dopo che il gruppo cinese della moda online ha comunicato un forte calo degli utili trimestrali, NEI SUOI PRIMI RISULTATI FINANZIARI SUCCESSIVI ALLA QUOTAZIONE (avvenuta il 1 settembre), alimentando le preoccupazioni degli investitori per la pressione sui margini e il rallentamento della crescita. Interviene Giulia Crivelli, Il Sole 24 Ore.Price cap carburanti. Chi è tagliato fuoriAutotrasporto, industria, agricoltura, pesca, cantieri e gli altri utilizzatori che acquistano carburante attraverso il canale all'ingrosso continuano oggi a pagarlo alle normali condizioni di mercato e non beneficiano della calmierazione. Ne parliamo con Cristian Maretti, Presidente Legacoop Agroitticoalimentare.

In this episode of The Atrium, host Alice Copperwheat speaks with Jessica Donington, Professor of Surgery and Chief of the Section of Thoracic Surgery at the University of Chicago, Illinois, USA, about neoadjuvant chemoimmunotherapy. Chapters 00:00 Intro 01:20 Why CT Surgery? 04:16 History 06:55 Patient Perception 08:42 Function, Why? 12:40 Patient Selection, Who? 18:20 Resectability 25:31 Types of Neoadj Therapy, What? 30:06 Evidence 33:01 Surgeon Responsibility 39:02 Robotics 39:54 Post Op Considerations 41:29 Key Points 43:12 Surgical Training Advice The discussion emphasizes the importance of being upfront and honest during patient conversations. It explores the benefits of neoadjuvant chemoimmunotherapy, how patients are selected for these treatments, and the various clinical trials on this topic. The conversation also addresses the chemo-radiation route and the clinical assessment of resectability. They also examine how to determine if a tumor is resectable and what factors are assessed during this process. It also highlights the need to consider whether a planned lobectomy might necessitate a pneumonectomy following neoadjuvant chemoimmunotherapy. The conversation also covers chemotherapy, immunotherapy, and targeted therapy, outlining what trainees should remember about each. Finally, they address the complexities of neoadjuvant chemoimmunotherapy, key takeaways for trainees, and the importance of working closely with the entire multidisciplinary team throughout the process. The Atrium is a monthly podcast presenting clinical and career-focused topics for residents and early career professionals across all cardiothoracic surgery subspecialties. Keep an eye out for next month's episode.     Disclosure Dr. Donington serves as an advisor, consultant, and speaker for AstraZeneca, BMS, Genentech/Roche, and Merck. Additionally, she acts as a consultant for Biodesix and an advisor for Lilly.     Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of recent breakthroughs and strategic moves that are shaping the future of drug development and patient care. Eli Lilly has achieved a significant milestone with the FDA's approval of Onswik, a once-weekly insulin therapy for type 2 diabetes. This innovative treatment is set to revolutionize diabetes management by offering a more convenient regimen, which could improve patient compliance and outcomes. Supported by robust phase 3 clinical trial data, Onswik is a testament to the importance of protein therapies in tackling metabolic diseases, highlighting Eli Lilly's commitment to advancing diabetes care. Additionally, Eli Lilly's collaboration with InnoCare Pharma exemplifies the trend of strategic partnerships playing an increasingly crucial role in accelerating drug discovery and development, focusing on five unmet medical targets with substantial financial milestones. In oncology, Elevar Therapeutics has received FDA approval for Lirafugratinib, a small molecule FGFR inhibitor targeting FGFR2-altered cholangiocarcinoma. This approval is a beacon of hope for patients with this challenging cancer type, emphasizing the potential of personalized medicine approaches in oncology. In another significant development, Elevar Therapeutics' FDA approval for Lyrfigtu marks a notable achievement as the first novel cancer drug from a Korean company to enter the U.S. market. This milestone underscores the global expansion of drug development capabilities and highlights Asian biopharmaceutical companies' growing influence. Promising clinical trial results continue to emerge. Merck's Remigromig demonstrated efficacy in a phase 2b/3 trial for diabetic macular edema as a Wnt pathway agonist, offering a novel approach in ophthalmology that could expand treatment options beyond VEGF pathways. In autoimmune diseases, Kyverna Therapeutics reported durable efficacy and safety for Mivocabtagene autoleucel in phase 3 trials for stiff person syndrome. This progress showcases the potential of CAR-T cell therapies in areas beyond oncology. Funding activities also highlight the sector's dynamism, with companies like Basecamp Research and BigHat Biosciences securing significant investments to advance AI-driven drug discovery platforms. These initiatives underscore the growing integration of artificial intelligence and machine learning in biopharmaceutical research—innovations that promise to expedite the identification and optimization of therapeutic candidates. On the regulatory front, Grail's Galleri multi-cancer blood test received positive recommendations from an FDA advisory committee. This liquid biopsy diagnostic holds promise for early cancer detection and screening advancements in precision medicine strategies in oncology. However, not all news is positive; Acadia Pharmaceuticals faced setbacks as its phase 2 trial for Remlifanserin missed primary endpoints in Alzheimer's disease psychosis, illustrating the challenges inherent in neurological drug development. Industry dynamics are further illustrated by Boehringer Ingelheim's strategic decision to offload its Shanghai CDMO to RAAS Blood Products, reflecting ongoing localization trends within pharmaceutical manufacturing. Meanwhile, AstraZeneca's Breztri received its third asthma-related approval from the European Commission, reinforcing its commitment to expanding its respiratory portfolio across key geographies. Additionally, legal actions such as the Florida Attorney General's lawsuit against three drug manufacturers and PBMs over alleged insulin price inflation highlight ongoing concerns about drug pricing. These actions may prompt further scrutiny and potential regulatory reforms within the pharmaceutical supply chain. Agentic AI is emerging as a pivotal trend in clinical trials, offering new models for connecting workflows and accelerating trial execution—a crucial advancement amid increasing trial complexity. Collectively, these developments illustrate an industry characterized by scientific innovation, strategic alliances, and regulatory achievements—all aimed at improving patient care and expanding access to novel therapies. As technological innovations like AI reshape clinical trials and companies navigate complex regulatory landscapes, the potential for breakthroughs in drug development remains high. These trends have profound implications for patient outcomes and the future direction of pharmaceutical research and development. Stay tuned as we continue to bring you more updates on these exciting advancements in our next episode.Support the show

As many of our listeners know from news reports, emergency departments have been under enormous strain in recent years trying to manage overcrowding, the opioid addiction crisis, the consequences of an under-resourced mental health system, and rising rates of violence against staff, among many other challenges. But our guest today guest thinks there's something else that should top that list. "I think hands down the most important issue is the reimbursement model," says Dr. Ryan Stanton, president-elect of the American College of Emergency Physicians. Dr. Stanton's uniquely-informed view is built on his work leading a physician-owned group staffing two Kentucky emergency departments, serving as EMS medical director for Lexington-Fayette County, and overseeing on-track medical response crews for auto racing series such as NASCAR. In this candid conversation with Raise the Line from Elsevier host Lindsey Smith, Dr. Stanton traces how underpayment from insurers is squeezing physicians and warping the incentives of emergency care, and why he believes the profession's ability to advocate collectively, not individually, is what will move the needle. This informative episode also explores: Why he thinks physician autonomy is the antidote to burnout; His approach to communicating medical information as a TV commentator; What it's like providing care at a NASCAR race when the “car is still smoking.” Mentioned in this episode: American College of Emergency Physicians If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of scientific advances and strategic collaborations shaping patient care and drug development globally. AstraZeneca recently achieved a significant milestone with the European Union's approval of Trixeo, a combination therapy for asthma. This approval follows a successful Phase 3 trial, highlighting its effectiveness in managing respiratory conditions through the combination of inhaled corticosteroids and bronchodilators. This not only broadens AstraZeneca's respiratory portfolio but provides European asthma patients with improved treatment adherence and outcomes due to the convenience of a single combined therapy. Simultaneously, Boehringer Ingelheim is expanding its partnership with Variant Bio, investing $250 million to integrate artificial intelligence and machine learning into cardiovascular drug discovery. This move underscores an industry-wide shift towards using advanced computational tools to accelerate drug development by identifying novel therapeutic targets. In another major development, Roche and Ionis Pharmaceuticals have reported promising results from their Phase 3 trial for Sefaxersen, an antisense oligonucleotide therapy for primary immunoglobulin A nephropathy. Achieving its primary endpoint, Sefaxersen is set on an accelerated approval pathway, offering new hope for patients with this kidney disease, which currently has limited treatment options focused mainly on symptom management rather than addressing underlying causes. The FDA's recent approval of Cordis' Selution SLR drug-coated balloon for coronary in-stent restenosis marks a pivotal innovation in treating this condition. Utilizing an mTOR inhibitor via a drug-coated balloon introduces a novel approach that could significantly reduce restenosis rates and minimize repeat interventions for patients with coronary artery disease. Roche is also making strides with Gazyvaro, which received MHRA approval for systemic lupus erythematosus following successful Phase 3 trials. As a monoclonal antibody targeting CD20 on B cells, it offers a new mechanism of action in autoimmune disease management, potentially transforming treatment paradigms by providing more targeted immunosuppression. On the business front, collaborations are driving innovation. Cellares' partnership with Seoul National University Hospital aims to automate hematopoietic stem and progenitor cell therapy manufacturing using their Cell Shuttle platform—an initiative that could overcome historical challenges in cell therapy production by enhancing manufacturing efficiency and consistency. Additionally, federated AI networks launched by companies like AbbVie and AstraZeneca represent a collective push towards enhancing drug discovery through data sharing while maintaining privacy. This approach improves predictive models for drug binding without compromising proprietary datasets, potentially expediting the identification of promising drug candidates. Despite these advancements, challenges persist. Immunovant's setback with imeroprubart in a Phase 2b trial for cutaneous lupus erythematosus highlights ongoing difficulties in treating complex autoimmune conditions. These challenges prompt industry leaders to advocate for EU policy reforms to counteract declining biotech competitiveness and sustain innovation momentum. Eli Lilly's dominance in the Medicare GLP-1 program, capturing 70% market share with 700,000 senior enrollees, underscores the growing acceptance of GLP-1 receptor agonists in managing diabetes and potentially obesity—a trend towards personalized chronic disease management. Meanwhile, Novo Nordisk is considering a direct listing on the New York Stock Exchange to enhance financial flexibility and increase its visibility among American investors. The industry is also witnessing significant investment in AI-driven drug discovery. Enveda Biosciences recently raised $311 million to advance its AI platform focused on obesity and inflammatory diseases—an investment signaling increasing reliance on AI to streamline drug discovery processes. The challenges within these innovations are notable as well. Immunovant's pivot away from lupus treatment following unsuccessful trials underscores the inherent risks of clinical development. Additionally, geopolitical shifts present both competition and collaboration opportunities as China's burgeoning biotech sector emerges as a formidable force. These developments collectively highlight a period of transformation for the pharmaceutical and biotech industries where strategic partnerships, technological advancements, and global market strategies are reshaping priorities and resource allocation. The relentless pursuit of innovation promises improved patient outcomes through novel therapies while navigating complex regulatory landscapes will be crucial to sustaining growth and addressing unmet medical needs globally. As we continue to witness these dynamic shifts, maintaining agility will be key to thriving amidst these evolving opportunities and challenges.Support the show

Co-hosts Ryan Piansky, a patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Science Advisory Council, interview Amarah, a high school senior and patient advocate living with EoE and several other chronic illnesses. Disclaimer: The information provided in this podcast is designed to support, not replace, the relationship between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.   Key Takeaways: [:48] Co-host Ryan Piansky introduces this episode, brought to you thanks to the support of APFED's Education Partners AstraZeneca, GSK, Sanofi, Regeneron, and Takeda. Ryan introduces co-host Holly Knotowicz.   [1:07] Holly introduces today's topic: eosinophilic esophagitis (EoE). EoE is a chronic allergic inflammatory disease of the esophagus.   [1:19] EoE occurs when eosinophils, a type of white blood cell, accumulate in the esophagus in elevated numbers, causing inflammation that can make eating or swallowing difficult or uncomfortable.   [1:30] Holly introduces and welcomes today's guest, Amarah, a high school student who is a patient advocate living with EoE. Welcome, and thanks for joining us.   [1:37] Amarah thanks Holly and Ryan and says she is very excited to be here.   [1:50] Amarah says she is a high school senior. She loves to perform and act. She is also very involved in sports and school activities. She is a cross-country member and a soccer member.   [2:05] Amarah was diagnosed with EoE when she was very young. She has done every treatment you can think of. She has had foods that she was able to eat, and then she couldn't eat them, and then later she could go back to eating them.   [2:19] Amarah says it feels like she has had "millions and millions" of scopes. She has done transnasal scopes and regular scopes.   [2:28] Holly says she and Ryan have been on numerous types of therapy and tried diet elimination. Holly has done the transnasal scope and is excited to hear that Amarah has. Ryan says he feels left out and needs to try a transnasal scope at some point.   [2:52] Holly says we also call it a nonsedated endoscopy. Holly says she loves that Amarah has access to it. Amarah says her state is sparsely populated without those resources, so she flies down to Phoenix, where she used to live, for all of her doctoring.   [3:27] Holly says it's awesome for listeners to know that Arizona is a state where they can get treatment.    [3:47] Amarah says she had a wonderful primary care doctor when she was little. She was having problems around eight months old. At about a year-and-a-half, her primary care doctor suggested she be tested for this "new" disease, EoE. So she got tested.   [4:16] Amarah remembers "not being able to eat anything." That was her normal. She doesn't remember having to take out any foods. The first time she realized she had something more than allergies, she was around 5 or 6 years old.   [4:37] At that time, she realized that something was not the same with other kids who have allergies. What she had was different from a normal allergy.   [4:50] Amarah says she was about 10 or 11 years old when she had a better understanding of what EoE was, inside the esophagus.   [5:16] Ryan compares Amarah's experience to his own, as he was also diagnosed very young. For years, he explained it away as allergies. It's a complicated thing to grasp when you're younger.   [5:45] Amarah is on dupilumab, which is helpful for her eczema, which has resisted topical treatments. Dupilumab also helps with her EoE, so now she is able to have dairy, wheat, and soy. She can't eat them at the same level as people who do not have EoE.   [6:27] Amarah says she prefers a lot of foods that do not have dairy and wheat in them. It's helpful for traveling. She can eat dairy, wheat, and soy, and her scopes come back clean, which is nice.   [6:44] Amarah says that in the past she has done budesonide. She is on PPIs. She had Nissen fundoplication. She also did a drug trial. When she was 12, her EoE got bad. She did a drug trial for an IV drug, and it did not work. She had an adverse reaction.   [7:24] Ryan says he was taking a medication for eosinophilic asthma, which was helping his EoE a little bit, but not a lot. Now that he is taking dupilumab for EoE, that is also helping him with his eosinophilic asthma. Ryan agrees that it is such a game changer.   [7:58] Amarah says she doesn't have other trigger foods, but she is allergic to shellfish due to IgE, not EoE. Peanuts and tree nuts trigger anaphylaxis. Soy, wheat, and dairy are definitely EoE triggers. She used to have to avoid corn but is able to have it now.    [8:38] Amarah says you just know when you eat too much of a food, and your EoE is starting to act up again.    [9:15] Ryan advises listeners to double-check with your care team before you start to introduce triggers back into your diet.   [9:26] Holly says this is so relatable. Holly is significantly older than Ryan and Amarah and didn't get diagnosed until she was older. She loves how Amarah articulated the different paths she has been on as she was growing up.   [9:55] Holly notes that Amarah was at the rise of new treatments that could give her hope to try.   [10:07] Holly asks Amarah to explain to listeners the Nissen fundoplication. Amarah says she had it when she was about four, for her GERD, which is acid reflux. She says some kids with EoE have it done; some do not.   [10:50] Amarah says the sphincter between her stomach and esophagus didn't fully close. The doctor said he had never seen a sphincter look so bad.   [11:04] They did surgery to take a part of the stomach and sew it up so the sphincter closes when food goes down the esophagus, so it stays in the stomach. Amarah says you should not be able to throw up after the surgery, but she still has that ability.   [11:42] Amarah says the surgery can get looser over the years. She has had a couple of tests where the doctors monitor how loose it is.   [11:50] Holly thanks Amarah for articulating what Nissen fundoplication is. Holly is fascinated that Amarah is still able to vomit. That's an important thing to think about with EoE. Holly had the same procedure twice before they knew she had EoE.   [12:53] Amarah says EoE has a lot of layers. It's very complicated. It's very hard to describe it. It takes a lot of extra steps [to manage it].   [13:05] Amarah explains using another diagnosis she has: mild dyslexia. She has to put in more effort and work to do school assignments because she's in advanced classes that require a lot of reading, writing, and spelling.   [13:25] EoE is similar in the way that you have to have the extra steps in order to manage it. She wishes people would know that it's a multi-step process. It's not just one and done.   [13:38] Amarah has been looking at colleges. One of the things she is looking for is whether they have cafeterias she can use. Do they have a disability program she can use and get accommodations for her needs? Do they have a kitchen she can use?   [13:57] Amarah says even though she can have all these different foods, she is still anaphylactic to peanuts and tree nuts. Because EoE can randomly flare up, it's important to her that she has those options.   [14:11] Amarah says EoE is very layered, and she wishes people would understand that more. It would be more helpful for the level of acceptance and understanding, overall, of having EoE, especially as a teenager.   [14:34] Ryan says that when he started college, he sat with the university dining hall and the office of disability services to explain his EoE, EoE triggers, and anaphylactic allergies, and to ask if he could eat at the dining hall. They offered the salad bar.   [15:03] The dining hall couldn't accommodate his needs, so he was able to get a dorm with a kitchen so he could prepare his own food.   [15:18] Ryan hopes that 10 years after Ryan started college, the university Amarah chooses will be more understanding of EoE and other allergies.   [15:56] Holly says that as a speech pathologist, she sees people with all diagnoses. There are still schools that don't consider EoE a disability. It's very important to think about accommodations. A patient chose to change schools because of the lack of accommodations.   [16:36] Holly is 42. When she went to school, she didn't know she had EoE, but she had IgE-mediated food allergies, threw up often, and could only eat certain things prepared certain ways. The school said she could eat at one dining hall, but it still wasn't safe.   [17:00] Holly says it has changed in a good way, but in some places, it has not, because some people still don't understand.   [17:11] Holly talks about Amarah avoiding corn and different things. People don't realize you can have an EoE trigger to very different types of foods, not just ones that you are IgE allergic to and need an EpiPen® for. That was key information for Amarah to bring up.   [17:35] Amarah enjoys participating in her school's speech, debate, and drama team. She used EoE as the topic for her informative speech project. Holly watched a video of it, and it was amazing. Holly asks how Amarah came up with the topic.    [19:16] Amarah says that the previous year she had done an informative speech on the history of My Little Pony, of which she is a fan. She decided that for the next year she would do an informative speech on one of the six chronic illnesses she has.   [19:56] Amarah considered which of her illnesses affected her the most. She picked EoE to learn more about it for herself and to explain it better to others, more than just saying she has allergies and can't eat that.   [20:03] Amarah wanted to create something that would be digestible by everyday people for a basic understanding. She had 10 minutes for the speech, so she didn't get into the nitty-gritty of it. She really liked that she got to share it with people.   [20:24] Amarah says she met a judge whose brother had just been diagnosed with EoE. She met another kid who had EoE. He told her he never thought he would see somebody talk about EoE in an informative speech.   [20:50] Amarah says that sharing about EoE was important. She loved doing it.   [20:57] Holly says she loves that Amarah used an outlet she enjoys to share something medically significant in her life.   [21:14] Holly shares how her soccer teammates reacted when she had problems swallowing. She didn't know she had more than food allergies. She and her teammates did a drama, with her as a character always having to vomit. It was releasing to do.   [22:02] Amarah says the informative speech was extremely therapeutic for her. One of her best friends since sixth grade told her, "I had no idea that's what that was." Sharing it with people was very helpful for Amarah and, she hopes, for others.   [22:35] Ryan says it was cool that she was able to connect with others with EoE or with relatives with EoE. It is a rare disease, but people can get the diagnosis more easily these days.   [22:51] Ryan says the speech was only 10 minutes, but Amarah fit so much in those minutes, clearly and concisely. He was very impressed.   [23:22] Amarah says she used 10 sources for her research. APFED was one of her sources. She learned about the number of people who have EoE. It was interesting to learn the difference between the world rate of EoE and the U.S. rate of it.   [24:00] Amarah had not known it was equally common among everybody. Age, gender, and ethnicity do not matter. That was cool to learn.   [24:18] Amarah says it was sad to learn of the lack of public awareness. She learned that the average age of diagnosis was 35 to 50 years old because people aren't aware of it. That was saddening for her.   [25:38] Holly says it can be a missed diagnosis for a time, and it creates more inflammation in certain areas to make things worse. Holly wasn't diagnosed until she was 25. People just thought she was attention-seeking to vomit all the time.   [26:13] Holly says her primary caseload is mostly people aged 18 and up who are newly diagnosed. It's not young kids who are getting diagnosed, like when she worked at a major children's hospital.   [26:39] Holly says Amarah's speech was very informative and well-articulated. It was also dramatic, like a performance, while giving a lot of good information. Holly says it helps people retain information if they're captivated by the presenter.   [27:18] Amarah hopes her peers learned a basic understanding of EoE and some of the ways it works. She covered different treatment plans and food trials, which her peers don't understand until she explains them. That was important to her.   [27:47] Amarah says trying to figure out a way to describe a food trial to somebody who did not know took her a lot of rewrites.   [27:57] Amarah says her last paragraph was about public awareness, why you should care about EoE, and what you should know about it. It's becoming a more prevalent disease.    [28:31] Amarah says that having a basic understanding of EoE creates more acceptance. That's one of the things Amarah hopes to improve in the world.   [28:48] This year, Amarah is writing a Persuasive Essay on why disability should be more prevalent in media because of the level of diversity that it could provide.   [29:03] A lot of people, when Amarah tells them about her disability and chronic illnesses, say, "I am so sorry for you. I feel so bad for you. That must be awful. It must be absolutely horrendous for you."   [29:20] Amarah says these are sometimes the same people who say that they care, but then they do not accept her or her food allergies. They don't accommodate her. They still eat peanuts around her and refuse to wipe their hands.   [29:45] Amarah sees there is a big difference between acknowledging it and accepting it. She used the speech to show people the disability and disease of EoE, some reasons they should know about it, and why they should accept it.   [30:10] Amarah used self-deprecating humor, one of her favorite things to do. Amarah has also done quite a few stand-up comedy acts, which involve self-deprecating humor. She says it's a little bit of a way to cope.   [30:32] Amarah wanted to make something that people would engage in. If she stood up there with a monotone voice for 10 minutes, nobody would remember anything.   [30:41] Amarah says performing like that and having a space where she could show a little bit more of herself that she doesn't normally show to people was not only therapeutic to her, but she hopes that it showed people what EoE is.   [31:04] Holly says, "You just made me cry." It's a hard life lesson when you have chronic illnesses. Holly and Ryan understand that.   [31:20] Holly tells how important it is to her to see disability in the media, whether it's a patient in a medical show that has EoE, or a model in a brand-name ad that uses a cane, as Holly does for a different disability. It hits her in a way that's different.   [31:58] Holly says that seeing and hearing things in the media that are a part of dealing with her disabilities makes her feel included in a way that she never felt with some of her "closest" peers at the time.   [32:12] Ryan says it's wonderful that Amarah is doing this advocacy work through an outlet that she really enjoys and spreading that awareness outside some of these patient advocacy communities. Lack of awareness is an issue.   [32:30] Ryan says people care and want to be accommodating, but if they don't understand it and it's not being presented to them in a way they can parse through and fully understand, it's hard for them to make those steps to be accommodating.   [32:43] Ryan is glad that Amarah is continuing her advocacy work through the essay she is working on in the Speech and Debate Club.   [32:52] Ryan reflects on how great it was to have Amarah join as a patient panelist at the Annual Patient Education Conference, EOS Connection 2026, in Denver, and answer questions for a sizeable audience.   [33:08] Ryan says it was wonderful to see a high school student fielding questions. It was helpful for all the participants in the audience as well.   [33:27] Amarah says she absolutely loved it. It was wonderful. She loved hearing the other panelists' patient stories, and in general, hearing every other kid's experience with EoE. They were all different.   [33:50] Amarah enjoyed sharing her story and having a platform to relate to people. She remembers saying, "You know when your EoE is acting up because you can't eat rice. It starts to get stuck in your throat," and everybody in the audience started nodding.   [34:21] Amarah says having that relatability was helpful. She loves speaking in front of an audience, so that was great, too.   [34:33] It was a different format from the informative speech. Amarah says having to think on her feet meant she had to be more conscious of the words she was going to say. Her informative speech had a written, memorized transcript. Even her hand movements were practiced.   [35:22] Amarah says being able to talk about her biases with EoE and experiences she has had was helpful for her, and she hopes for other people, but very different from her informative speech, which is not supposed to be biased at all. It's not persuasive.   [35:48] Amarah says there were multiple times when she was writing her informative speech that she realized she could not put a sentence in it because it showed bias. She couldn't say, "you shouldn't be mean to people with EoE," for example. That's bias.   [36:21] Amarah says on the patient panel, she was able to do that. A lot of the experiences that she related on the patient panel were things she may have told her parents and some family members, but not anyone in her friend group.   [36:48] Amarah says sharing these experiences and how some of those events had made her feel or had impacted her was something she was not able to show in her informative speech. It was helpful to share her experiences on the patient panel.   [37:26] Ryan says, for our listeners, you can still access the patient panel online. We have on-demand content. We'll link to that in the show notes for this episode.   [37:36] Ryan says people can go back and watch that and hear from you and our other patient panelists. We had a great range of panelists up there. Ryan asks if Amarah learned anything that stuck with her from the panelists or presenters at this conference.   [37:52] Amarah says one of the patient panelists was talking about EoE in the workforce at her job. That was not something Amarah had thought about before. She found it really helpful and something that she will have to think about more in the future.   [38:13] Amarah met a teen who talked about his experiences of having EoE while being on sports buses and sports teams. Amarah found it helpful as she is on sports teams. The student told everyone on his team about his EoE. Amarah found that interesting.   [38:47] It gave Amarah some ideas on how to talk to people on her teams. Amarah just loved meeting all of the people at Eos Connection and learning about their different experiences and how she could improve some of her future experiences.   [39:10] Holly says a key point of the conferences is learning what's coming next in terms of treatment, diagnosis, and all the wonderful things you see health providers doing to support this diagnosis in the world.   [39:29] Holly says when you meet someone else who's going through a very similar experience, there is nothing quite like it. Holly talks about learning from the positive attitudes of other patients she meets at the conferences.   [40:12] Amarah tells EoE patients, "You don't have to tell people if you don't want to." She is a very private person when it comes to her medical stuff, especially during a flare or when there is something new happening.   [40:45] Amarah says she doesn't share it with people until she fully knows what's going on. "You don't have to share it with people if you don't want to."   [40:54] Amarah continues, "Granted, you should probably share your anaphylaxis with your teachers. 'Please don't bring peanuts in the classroom; you will kill me.' But you don't have to get into the nitty-gritty."   [41:06] Amarah continues, "You can just say, 'I have a medical disease. It affects me on a daily basis. I don't want to talk about it.' That is completely OK."   [41:17] Amarah continues, "You do not have to explain anything to somebody. You are not required to. You don't have to. It is your own body. It is your own choice when telling people things."   [41:31] Amarah continues, "It sucks sometimes, and especially kids with EoE, they may have a lot of other chronic illnesses, like me, where everything is combined at once."   [41:48] Amarah continues, "Once something flares up, then the other thing flares up. It sucks sometimes. And that is OK. It is OK that it sucks sometimes. You just have to get through it. You can't wallow in it, but you can acknowledge it."   [42:07] Amarah continues, "If you sit there and 'everything is fine, everything is great,' well, you know, you're actively having a reaction; it's clearly not. And that is something that I still work on today: pretending that everything is fine when it's not."   [42:26] Amarah continues, "You're not going to be perfect. I'm still not perfect. I struggle with talking to people, sharing my experiences, pretending that everything is fine even though I need help, or using self-deprecating humor when it's a serious problem."   [42:52] Amarah continues, "You're not perfect. That's OK.   [42:58] Ryan says that's such a good thing to keep in mind for the patients out there, that it's a journey. There are ups and downs. Finding your comfort level and maturing about the disorder, and keeping in mind that it's not going to be a perfect day every day.   [43:16] Ryan says, Amarah, I'm really glad you were able to join us on this podcast. It was so good to see you at the conference over the summer, as well.   [43:21] I think you're such a wonderful patient advocate. I'm so inspired to see you engaging so much with the community both at APFED and more broadly, speaking about your eosinophilic disorder through these other outlets that are meaningful to you.   [43:39] I know all our listeners are going to appreciate that as well.   [43:44] For our listeners who do want to learn more about eosinophilic disorders, we encourage you to visit apfed.org and check out the links in the show notes.   [43:50] If you're looking to find specialists who treat eosinophilic disorders, we encourage you to use APFED's Specialist Finder, available at apfed.org/specialist.   [44:00] If you have personally been impacted by eosinophilic disorders and are interested in sharing your experiences, please check out apfed.org/shareyourstory.   [44:09] If you'd like to connect with others impacted by eosinophilic diseases, please join APFED's online community on the Inspire Network at apfed.org/connections.    [44:20] Ryan thanks Amarah for joining us. This was such a wonderful conversation, and I'm really glad that we were able to have this discussion today.   [44:27] Amarah thanks Ryan and Holly. "I do appreciate it. This was wonderful."   [44:32] Holly thanks APFED's Education Partners AstraZeneca, GSK, Sanofi, Regeneron, and Takeda for supporting this episode. Holly thanks Amarah.   Mentioned in This Episode:   APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast apfed.orgapfed.org/specialist apfed.org/connections Eos Connection 2026 Education Partners: This episode of APFED's podcast is brought to you thanks to the support of AstraZeneca, GSK, Sanofi, Regeneron, and Takeda.   Tweetables (Edited):   "I love to perform and act. I am also very involved in sports and school activities. I am a cross-country member and a soccer member. I was diagnosed with EoE when I was very young." — Amarah   "It feels like I have had 'millions and millions' of scopes. I have done transnasal scopes and regular scopes." — Amarah   "I remember not being able to eat anything. That was my normal. I don't remember having to take out any foods. The first time I realized I had something more than allergies, I was around 5 or 6 years old." — Amarah   "EoE is very layered, and I wish people would understand that more. It would be more helpful for the level of acceptance and understanding, overall, of having EoE, especially as a teenager." — Amarah   "Having a basic understanding of EoE creates more acceptance. That's one of the things I hope to improve in the world." — Amarah   Guest Bio: Amarah is a high school senior living in Montana. She has EoE and several other chronic illnesses. She loves public speaking and acting. A fun fact about Amarah is that she owns 14 wigs (she loves to create costumes).

This week, Chief Content Officer Matt Davis sits down with Arun Krishnan – SVP, Global Supply Chain & Strategy at AstraZeneca – to explore the Holy Grail of modern operations: the self-healing supply chain. Pulling back the curtain, Arun shares how AI and human judgment are combining to automate the routine, eliminate the guesswork, and protect patient safety at scale, all while bringing a genuine sense of joy back to the team by freeing them up for higher-level work.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a period of profound transformation within the industry, marked by scientific advancements, strategic acquisitions, and a shifting regulatory landscape that promises to redefine the future of healthcare. Telix Pharmaceuticals has made headlines with its acquisition of ITM Isotope Technologies Munich SE, valued at up to $2.35 billion. This move positions Telix at the forefront of the radiopharmaceutical sector—a field gaining momentum due to its precision medicine potential in oncology. Radiopharmaceuticals use radioactive substances for targeted cancer therapies, offering promising alternatives to traditional treatments by minimizing side effects and enhancing therapeutic efficacy. This acquisition could revolutionize oncology treatment protocols, providing more precise diagnostic and therapeutic options for patients. In another significant development, Ultragenyx has secured FDA approval for Fayuvi, marking the first-ever gene therapy for Sanfilippo Syndrome Type A. This devastating neurodegenerative condition previously had no effective treatment. Gene therapies like Fayuvi represent a paradigm shift in addressing genetic disorders by tackling root causes at the molecular level rather than merely alleviating symptoms. This milestone not only offers hope to affected families but also sets a precedent for future gene therapies targeting similar rare diseases. China's ambitious five-year plan to capture 25% of global innovative drug approvals by 2030 underscores its growing role in the pharmaceutical industry. With a focus on expanding research and development capabilities across multiple disease areas, this initiative aims to foster international collaborations and accelerate novel therapies' introduction worldwide. The plan reflects China's commitment to becoming a major player in pharmaceutical innovation, potentially reshaping global market dynamics. Alkermes' recent clinical trial results highlight another promising development in ADHD treatment. Its orexin agonist ALKS 7290 has shown potential in Phase 1b trials, with Phase 2 trials underway. Orexin agonists could represent a new approach to managing ADHD beyond traditional stimulant medications by addressing underlying neurobiological pathways rather than just symptoms. Beacon Therapeutics is preparing for an FDA filing following successful Phase 2/3 trials of laruparetigene zovaparvovec for X-linked retinitis pigmentosa (XLRP), a progressive eye disease leading to blindness. This advancement underscores gene therapy's potential to significantly slow disease progression or restore vision in patients with inherited retinal diseases, offering renewed hope for affected individuals. Strategically, Novo Nordisk is realigning its focus through acquisitions like Kallyope's early-stage obesity assets and Bayer's divestment of the cancer drug Stivarga to Grunenthal. These transactions reflect ongoing efforts within companies to concentrate on core competencies and address competitive pressures effectively. AstraZeneca's $30 million investment in its Wuxi facility aims to expand cardiovascular drug production capacity, responding to rising global demand driven by increasing incidence rates. Such investments highlight a broader trend towards enhancing production capabilities in response to changing market needs. Eli Lilly has also made strides in oncology with FDA approval of an oral SERD combination therapy involving Inluriyo and Verzenio. This combination offers longer progression-free survival for breast cancer patients compared to monotherapy, representing an important advancement in developing patient-centric therapeutic regimens. Finally, technological advancements continue redefining clinical trial processes with automation and digital innovations accelerating drug development timelines and improving data integration capabilities. These efforts will likely lead to transformative impacts on drug development processes and patient outcomes globally. Overall, these developments illustrate an industry at the forefront of innovation, grappling with complex challenges such as regulatory changes and competitive pressures while continuously pushing the boundaries of medical science to improve patient care. As biotechnologies advance and new therapeutic areas are explored, stakeholders across the sector must navigate these changes strategically to capitalize on emerging opportunities. Thank you for tuning into Pharma Daily. Stay informed and engaged as we continue bringing you the latest insights from the pharmaceutical and biotech world—it's an exciting time for science and medicine alike!Support the show

This episode has been funded by AstraZeneca and is intended for healthcare professionals. All content has been developed independently by AMJ, and AstraZeneca has had no influence over the content of this podcast. The views expressed are those of the participating experts and do not necessarily reflect the views of AMJ or AstraZeneca. This material is intended for educational and scientific exchange purposes only. Thoracic medical oncologist Julia Rotow and neuro-oncologist David O. Kamson discuss how they manage central nervous system metastases in EGFR-mutated advanced non-small cell lung cancer. They begin with brain metastases found at diagnosis, and how the current frontline regimens have changed the decision between systemic therapy with MRI surveillance, upfront stereotactic radiosurgery, and, for some patients, both. They also explain where whole brain radiotherapy now sits in their own practice. The speakers then discuss leptomeningeal disease: why it is often recognized late, what they add to the standard workup, and the symptoms that make them worry about hydrocephalus and cauda equina involvement. They review systemic and local options after progression on a third-generation tyrosine kinase inhibitor, and close with where they each see the biggest gap in current central nervous system management. Speakers David O. Kamson, Johns Hopkins University, Baltimore, Maryland, USA Julia Rotow, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

The Bank of England held the base interest rate at 3.75% last Thursday by a six to three vote, the dissenters favouring an immediate increase, and warned that rates may need to rise if the energy shock feeds into more persistent inflation. It also slowed balance sheet reduction, giving gilt markets relief and leaving the 10-year yield five basis points lower at 5.29%. The decision followed consumer price index ("CPI") inflation of 3.1% for the year to August, up from 2.9% on higher motor fuel costs, though Core CPI (which excludes energy, food, alcohol and tobacco) held at 2.6% and CPI services at 3.4%. Unemployment held at 4.9% in the three months to July against the 5% expected....Stocks featured:Airtel Africa, AstraZeneca and Barratt RedrowTo find out more about the investment management services offered by Walker Crips, please visit our website:https://www.walkercrips.co.uk/This podcast is intended to be Walker Crips Investment Management's own commentary on markets. It is not investment research and should not be construed as an offer or solicitation to buy, sell or trade in any of the investments, sectors or asset classes mentioned. The value of any investment and the income arising from it is not guaranteed and can fall as well as rise, so that you may not get back the amount you originally invested. Past performance is not a reliable indicator of future results. Movements in exchange rates can have an adverse effect on the value, price or income of any non-sterling denominated investment. Nothing in this podcast constitutes advice to undertake a transaction, and if you require professional advice you should contact your financial adviser or your usual contact at Walker Crips. Walker Crips Investment Management Limited is authorised and regulated by the Financial Conduct Authority (FRN: 226344) and is a member of the London Stock Exchange. Hosted on Acast. See acast.com/privacy for more information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking advancements and strategic shifts shaping the future of this dynamic industry. The FDA has recently approved Ultragenyx's gene therapy, Fayuvi, for a rare neurodegenerative disorder, marking a significant milestone in the realm of precision medicine. Gene therapies like Fayuvi offer a beacon of hope for conditions with limited treatment options. This approval underscores the burgeoning promise of personalized medicine, where treatments are meticulously tailored to individual genetic profiles, vastly improving patient outcomes. Across the Atlantic, Europe's Committee for Medicinal Products for Human Use has given the nod to several new medicines, including notable contributions from Novo Nordisk and AstraZeneca. Novo Nordisk's latest hemophilia A treatment exemplifies its ongoing commitment to enhancing therapeutic solutions for blood disorders. These CHMP endorsements are pivotal; they pave the way for European Commission approvals, thereby bringing these advanced treatments one step closer to patients throughout Europe. In a significant breakthrough for diabetes-related complications, Bayer's Kerendia has become the first drug in three decades approved by the FDA specifically for chronic kidney disease linked to type 1 diabetes. This approval highlights a critical advancement in addressing long-standing unmet medical needs, emphasizing the necessity of continuous innovation in chronic disease management. However, not all developments have been straightforward. Bristol Myers Squibb has opted to discontinue its degrader-antibody conjugate following an evaluation of Phase 1 data. This decision illustrates the high stakes of drug development where early-stage data critically inform strategic directions and resource allocations. It serves as a reminder of the inherent risks involved in pioneering new therapeutic approaches. In obesity management, oral GLP-1 receptor agonists are seeing fluctuating prescription trends as market competition intensifies between Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo. A weekly tracker launched by Fierce Pharma seeks to illuminate these trends, offering valuable insights into market dynamics and the evolving landscape of weight-loss therapies. From an investment perspective, Electra Therapeutics' $350 million IPO marks investor confidence in biotech companies focused on inflammation-related diseases. The funds raised are earmarked for advancing its monoclonal antibody Ipsoprubart aimed at treating immune-mediated conditions. This trend towards leveraging financial markets reflects a broader industry movement aimed at fueling innovation and expanding therapeutic portfolios. Notably, despite geopolitical tensions, drug licensing deals in China remain largely unaffected by new U.S. Treasury rules. This stability is crucial for maintaining cross-border collaborations essential to global drug development efforts. On another front, Xenon Pharmaceuticals has paused its phase 3 depression trials due to psychosis events, underscoring the complexities inherent in psychiatric drug development. This pause highlights the rigorous safety evaluations necessary during clinical trials to ensure patient welfare is prioritized. Exploring broader industry trends, cyclic peptides are gaining attention for their potential to break into new drug frontiers despite manufacturing challenges. Their versatility across various therapeutic areas underscores their promising future in drug development. Moreover, the FDA's open stance towards emerging fields like psychedelics reflects a progressive regulatory approach towards novel therapeutic avenues while ensuring safety standards are upheld. This openness holds promise for groundbreaking treatments targeting complex conditions such as PTSD and depression. These developments collectively signify a dynamic period within the pharmaceutical and biotech sectors marked by rapid innovation and strategic recalibration. As companies adeptly navigate regulatory landscapes and clinical challenges, successful approvals and strategic pivots underscore their resilience and commitment to advancing patient care through cutting-edge science. The continual evolution of technologies like gene therapy and monoclonal antibodies promises transformative impacts on disease management and patient outcomes as we move forward into an exciting future for healthcare advancements globally. Thank you for listening to Pharma Daily. Stay tuned for more updates on how these developments continue to shape our industry and transform patient care around the world.Support the show

AT&T, Nippon Steel, AstraZeneca, PayPal are part of the fun this week. 245 breaches total!

Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal advancements and strategic maneuvers shaping the landscape of drug development and patient care. Bayer's Kerendia, known generically as finerenone, has achieved its third FDA approval, this time targeting chronic kidney disease linked with type 1 diabetes. This small molecule mineralocorticoid receptor antagonist plays a critical role in mitigating fibrosis and inflammation—key factors in chronic kidney disease progression. Given the high prevalence of kidney complications in diabetic patients, this approval marks a significant step forward in managing such conditions. Its mechanism offers a novel approach to addressing cardiovascular and metabolic disorders, underscoring its vital role in contemporary therapeutic strategies. In regulatory advancements, AstraZeneca and Daiichi Sankyo's Enhertu has secured approval from NICE for treating HER2-low breast cancer. This marks a significant transition toward precision medicine, allowing the NHS to provide more targeted cancer therapies. Enhertu, an antibody-drug conjugate, exemplifies the shift towards precision oncology by delivering cytotoxic agents directly to cancer cells expressing HER2, thus opening new avenues for personalized treatment strategies. Japan's MHLW has given the green light to GSK's Shingrix in prefilled syringe form for shingles prevention. As a recombinant zoster vaccine enhanced by an adjuvant system, Shingrix represents cutting-edge vaccine technology aimed at strengthening immune responses against the varicella-zoster virus. This approval not only broadens preventative measures but also highlights advancements in vaccine delivery systems. Novo Nordisk's collaboration with Orbis Medicines is another noteworthy development, focusing on oral macrocycle therapies for cardiometabolic conditions—a partnership with potential milestones valued at $1.4 billion. This move aligns with Novo Nordisk's strategic push into small molecule drug discovery to address unmet needs in cardiovascular and metabolic disorders, echoing a broader industry trend towards innovative therapeutic approaches. Meanwhile, Roche has ventured into an agreement with Dualitas Therapeutics to develop bispecific antibody platforms for autoimmune diseases. With an upfront payment of $36.5 million and potential milestone payments reaching $1 billion, this collaboration underscores the burgeoning interest in bispecific antibodies' capacity to target dual antigens simultaneously—offering promising new pathways for treating complex immunological conditions. On the clinical trial front, Roche's Lunsumio has met its Phase 3 primary endpoint, showcasing improved progression-free survival in patients with relapsed or refractory follicular lymphoma. This bispecific antibody exploits the immune system by targeting CD20 on B-cells while engaging CD3 on T-cells, highlighting its potential as an effective option for difficult-to-treat cancers. Conversely, Longeveron's laromestrocel faced setbacks in its Phase 2b trial for hypoplastic left heart syndrome—a reminder of the complexities inherent in developing cell therapies for cardiovascular diseases. Such challenges highlight the critical need for innovative approaches and continued perseverance within clinical development. Regulatory scrutiny remains a pertinent issue as evidenced by the FDA's warning letter to Bausch & Lomb over contamination concerns. This action emphasizes ongoing challenges within ophthalmology manufacturing standards and regulatory compliance—critical aspects that demand rigorous attention to ensure patient safety. These developments collectively reflect an industry characterized by dynamic scientific advancements and strategic collaborations aimed at addressing pressing health challenges through cutting-edge drug development and precision medicine. As companies continue to invest in innovative research and form strategic alliances, these efforts offer significant promise for improving patient outcomes through more effective and targeted therapies. The evolving regulatory landscapes and technological advancements will undoubtedly shape these trends further, offering new opportunities for growth and breakthroughs in patient care. The commitment to overcoming complex challenges remains at the forefront of industry priorities as stakeholders strive to deliver impactful treatments to patients worldwide. Thank you for tuning into Pharma Daily; stay with us as we continue to explore these transformative developments shaping the future of healthcare science.Support the show

Limiting the side effects of cancer treatments has been an animating force in the field of oncology for many years, and there's been progress to report on that front, but what if you could target cancer tumors without using radiation or chemotherapy and instead generate heat from inside the tumor to kill cells? That's the quest of our guest today, Dr. Hadiyah-Nicole Green, whose promising research using lasers and nanoparticles to eliminate tumors received Breakthrough Device Designation from the FDA earlier this year. “The laser beam that we're using is low power like a laser pointer, and without activation by the laser, the nanoparticles are harmless. Both are targeted just at the site of the tumor so because we don't use systemic delivery, we avoid all of the systemic side effects,” she explains.Dr. Green is also the founder and president of the Ora Lee Smith Cancer Research Foundation, named for an aunt who raised her and who died of cancer without pursuing curative treatment because of her fear of the side effects. Shortly after, her aunt's husband also died of cancer, opting for treatments that took a heavy toll on his body. “At 22 years old, I saw the horrors of cancer and the horrors of cancer treatment and just felt in my heart that there has to be something better than this,” she tells host Michael Carrese.On this fascinating episode of Raise the Line from Elsevier, we'll explore the science behind Dr. Green's approach, the challenges of raising the millions of dollars needed for human clinical trials, and rethinking the current funding landscape for cancer treatments.Mentioned in this episode:Ora Lee Smith Cancer Research Foundation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

This episode covers:  The role of AI in heart failure and prevention AI advances in interventional cardiology Training cardiologists of the future Host: Fielder Camm Guests: Benjamin Meder, Pim van der Harst, Jozine ter Maaten and Mark Westwood Want to watch that episode? Go to: https://esc365.escardio.org/event/2554 Disclaimer: ESC TV Today is supported by Novartis and Novo Nordisk through independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests: Stephan Achenbach, Dan Atar, Yasmina Bououdina, Fielder Camm, Nicolle Kraenkel, Jozine Ter Maaten, Pim Van der Harst and Mark Westwood have declared to have no potential conflicts of interest to report. Carlos Aguiar has adeclared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Benjamin Meder has declared to have potential conflicts of interest to report: Alexion, Alynlam, Amgen, Apple Inc., AstraZeneca, Bayer AG, BNK, Biontech, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cytokinetics, Daiichi Sankyo, Deutsche Gesellschaft für Kardiologie, German Center for Cardiovascular Research, German Research Foundation, Hummingbird Diagnostics, Intellia, Johnson&Johnson, Klaus-Tschira Foundation, Informatics for Life, Leducq Foundation (CASTT), Novartis, Novo Nordisk, Pfizer, SA, Sixt, SMT, Space X, Zoll. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode delves into some of the latest breakthroughs, regulatory updates, and strategic maneuvers reshaping the landscape of drug development and patient care. Starting with remarkable advancements in drug approvals, Scholar Rock's Isembldy (apitegromab), a monoclonal antibody designed to inhibit myostatin, has secured FDA approval for treating spinal muscular atrophy. This approval came after successful Phase 3 trials and marks a significant milestone in managing neuromuscular diseases. By targeting the myostatin pathway, which regulates muscle growth, Isembldy offers hope for improved motor function in patients suffering from this debilitating condition. Meanwhile, Pharming's Joenja (leniolisib) received an expanded label from the FDA, now approved for pediatric patients aged four and older with activated phosphoinositide 3-kinase delta syndrome, reflecting ongoing efforts to tackle rare autoimmune disorders. Telix Pharmaceuticals has also made strides with the approval of Pixclara (floretyrosine F 18) for PET imaging of glioma, enhancing diagnostic precision for both adult and pediatric brain cancer patients. In clinical trial successes and challenges, GSK and Hansoh Pharmaceutical reported that their antibody-drug conjugate, risvutatug rezetecan, significantly reduced the risk of death in Phase 3 trials for relapsed small-cell lung cancer by 54%. This underscores the potential of targeted therapies in oncology, especially where second-line treatments have been limited. AstraZeneca's Tagrisso (osimertinib), meanwhile, continued to demonstrate its efficacy with a notable reduction in death risk in early-stage EGFR-mutated non-small cell lung cancer at an eight-year follow-up, reinforcing its value as an adjuvant therapy. However, AstraZeneca faced setbacks with camizestrant's Phase 3 trial failing to meet primary endpoints in estrogen receptor-positive breast cancer. A similar challenge arose with Enhertu (trastuzumab deruxtecan) in HER2-mutant non-small cell lung cancer, indicating ongoing difficulties in developing effective combination therapies. Turning to strategic business developments, Johnson & Johnson's decision to divest its orthopedics unit DePuy Synthes to Apollo Equity Management for $20 billion reflects a strategic refocus on core areas like pharmaceuticals and medical devices. Similarly, Novo Nordisk's rebranding as 'Novo' signals an effort to strengthen its competitive stance against Eli Lilly within the GLP-1 agonist market, crucial for managing metabolic disorders such as diabetes. In collaborations and licensing deals aimed at broadening access to healthcare innovations, Bio Usawa's partnership with Axmed is set to enhance access to affordable biologic medicines across Africa, a vital step towards expanding healthcare reach in underserved regions. In oncology research advancements, Owkin has licensed its AI-driven K Pro scientist platform to Servier to accelerate drug discovery through artificial intelligence and machine learning applications. Regulatory challenges continue to shape industry dynamics. The FDA has postponed its decision on Exelixis's Zanzalintinib combined with Roche's Tecentriq for metastatic colorectal cancer until March 2027, reflecting rigorous scrutiny to ensure safety and efficacy. Meanwhile, Cellectis has opted to halt its allogeneic CAR-T programs amid increasing competition from in vivo approaches, showcasing strategic adaptability within the rapidly evolving field of cell therapy. In recent news focusing on mRNA technology and personalized cancer vaccines, Moderna's flu vaccine approval using mRNA technology marks a pivotal moment for this platform after facing skepticism over the years. Furthermore, Moderna and Merck have reported positive Phase 3 results for their personalized mRNA-based cancer vaccine—an advancement positioning them as leaders in personalized cancer immunotherapy following success in melanoma treatment. The sector remains dynamic as companies navigate these complex environments. Breakthroughs such as ivonescimab's success provide optimism for future innovations that could significantly enhance patient care and treatment outcomes across various diseases. The emphasis on mRNA technologies and personalized medicine heralds a new era of targeted therapies poised to redefine standards of care across multiple disease areas. As these initiatives progress, they hold potential not only for improving existing treatment paradigms but also for pioneering new frontiers in healthcare delivery. As these developments unfold, they highlight the industry's dual focus on advancing scientific innovation while navigating complex regulatory landscapes and competitive pressures. The implications are profound: promising enhanced patient outcomes through novel therapies while prompting strategic realignments among key industry players. These initiatives not only aim to improve existing treatment paradigms but also pioneer new frontiers in healthcare delivery.Support the show

In Episode 24 of Season 7 of Driven by Data: The Podcast, Kyle Winterbottom is rejoined by David Castro-Gavino, Executive Director, Head of Data Deployment at AstraZeneca, and joined by his co-author Boyan Angelov, Principal Strategist at Exxeta, where they discuss their new book, Enabling Data, and why the data industry is still stuck in Groundhog Day. The same three arguments – who owns that number, is it right, and why does it take so long – have been repeating for thirty years, and rather than fixing them, the industry keeps renaming the problem.The conversation covers why most complexity in data is self-inflicted, why maturity models are "data theatre" compared to diagnosing friction, and why AI hasn't solved any of this – it has poured fuel on the fire.They also discuss:Why the industry has a short collective memory and keeps rediscovering problems solved twenty years ago.What the three recurring arguments are that every data organisation keeps having.Why renaming the symptom – big data, data mesh, platforms – never fixes the underlying problem.How a simple pizza business becomes a data nightmare the moment it goes digital.Why most complexity in data is self-inflicted, and why that is good news.Why "technology is not the problem, you are" is deliberately provocative.What four questions to ask before going back to the market for a new tool.Why fixing the system, not the tool, is the maxim that matters.Who the "merchants of complexity" are, and why consultants are usually the culprits.Why making things simple is the hardest job in data.What's wrong with using maturity scores as the objective.Why measuring the wrong things promotes the wrong behaviours.How to practically find friction by refusing to accept the first answer.Why friction looks different for an analyst, an engineer and a business leader.Why not every foundational problem needs to be solved, and how to avoid spending forever in the basement.Why data teams that don't understand the business are missing the biggest opportunity.What the cargo cult is, and why copying Spotify's operating model won't make you Spotify.How the enabling model's four pillars – people, governance, technology and enablement – fit together.Why the fragility of senior data leadership is structural rather than personal.Why data doesn't create friction in an organisation, it reveals it – and gets blamed for it.Why a clear mandate matters more than who the CDO reports to.Why the industry needs to stop hiring data leaders on a shopping list of technical skills.How AI has exposed how little progress most companies have actually made on the fundamentals.Thanks to our sponsor, Data & AI Literacy Academy.Data & AI Literacy Academy is leading the way in transforming enterprise workforces with data literacy across the organisation, through a combination of change management and education. In today's data-centric world, being data literate is no longer a luxury, it's a necessity.If you want successful data product adoption, and to keep driving innovation within your business, you need to start with data & AI literacy first.At Data & AI Literacy Academy, they don't just teach data skills. They empower individuals and teams to think critically, analyse effectively, and make decisions confidently based on data. They're bridging the gap between business and data teams, so they can all work towards aligned outcomes.From those taking their first steps in data & AI literacy to seasoned experts looking to fine-tune their skills, our data experts provide tailored classes for every stage. But it's not just learning tracks that they offer. They embed a deep data culture shift through a transformative change management programme.They take a people-first approach, working closely with your executive team to win the hearts and minds. We know this will drive the company-wide impact that data teams want to achieve.Get in touch and find out how you can unlock the full potential of data in your organisation. Learn more at www.dl-academy.com/drivenThanks to our sponsor FOIL AIFOIL are an AI consultancy, and one of the most exciting to watch right now.​Fast-growing, genuinely ambitious, and refreshingly down to earth, with a leadership team who have been doing this for years and are well respected for it.​FOIL push data leaders to claim a voice at the top table, to lead the business rather than trail behind it with a handful of AI productivity tools. They push the point that if every competitor has the same tools, productivity is not an advantage. The real prize with AI is bigger and FOIL have the expertise – both strategic and technical – to push the boundaries of what your organisation can achieve, in a practical way. ​FOIL are a lot bolder and braver that the traditional consultancy. That confidence comes from deep practitioner expertise, and it shows in how they engage with their partnerships.​They are claiming the phrase: the autonomic business. A business that senses what is happening, decides within clear guardrails, adapts as things change, and keeps improving on its own. Intelligence built into how the company runs, and they've just been recognised at the British Data Awards for their work with Welsh Water on exactly this concept.​Learn more at https://foilai.co.uk/

Unexpected Career Transitions can blindside us, but also become teachers for us in the next chapter.Ruchika Singhal is a Reinvention Coach, speaker, podcast host, and founder of Elevare Advisory.A Wharton MBA with nearly 30 years of leadership experience across Johnson & Johnson, AstraZeneca, and Medtronic, she has led businesses, built high-performing teams, and driven growth across India and Asia Pacific.But her most transformative leadership lesson didn't come from the boardroom.After an unexpected career transition, Ruchika found herself facing a question many successful professionals secretly fear.Who am I when the title disappears?That experience became the catalyst for a new chapter. Today, she helps senior professionals navigate:Career TransitionsIdentity ShiftsConfidence CrisesReinvention She has also created the Reinvention Playbook that she uses for corporations and individuals as they process this new season. CONNECT WITH RUCHIKA:Website: https://www.elevareadvisory.orgLinkedIn: https://www.linkedin.com/in/ruchikasPodcast (Lead with Ruchika): Spotify & Apple PodcastsInstagram: @singhal_ruchika CONNECT WITH DEBIWebsite – https://www.debironca.comYouTube - https://www.youtube.com/@DebiRoncaOfficialInstagram - @debironcaEmail – info@debironca.comFree Group Coaching - https://debi.sequoiatransitioncoaching.com/group-coaching Check out my online course!Your Story's Changing: Finding Purpose in Life's Transitionshttps://course.sequoiatransitioncoaching.com/8-week-programThe Family Letter by Debi Ronca – International Bestsellerhttps://www.amazon.com/dp/B07SSJFXBDFree Clarity Call: https://calendly.com/debironca/free-clarity-call

Welcome back to the IDEA Collider podcast. In this second instalment of our future of immuno-oncology series, Alex Gray is joined by colleagues David Radwaner and Tom Brockbank to discuss what lies ahead for cancer immunotherapy. As the industry prepares for the upcoming patent expiration of Merck's dominant checkpoint inhibitor Keytruda, companies are racing to claim the next oncology backbone. We analyze the three major strategies currently shaping the pipeline: Merck's platform defense focusing on subcutaneous formulations and early-stage curative intent; the high-risk, high-reward displacement play of PD-1/VEGF bispecific inhibitors spearheaded by players like Akeso and Summit; and AstraZeneca's tailored, tumor-specific approach combining immunotherapy with antibody-drug conjugates (ADCs) and targeted small molecules. The guests also dissect key clinical insights from the HARMONY-6 Phase 3 trials, the biological and tumor-localization benefits of dual-mechanism molecules over dual-drug cocktails, and the strategic importance of choosing between incremental portfolio expansion and blockbuster-seeking big bets. Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Alex Gray; LinkedIn: https://www.linkedin.com/in/alexander-gray-934a653/ Keep up with David Radwaner; LinkedIn: https://www.linkedin.com/in/david-radwaner-1b496343/ Keep up with Tom Brockbank; LinkedIn: https://www.linkedin.com/in/tom-brockbank-159bb4116/ Follow IDEA Pharma On; Website: https://www.ideapharma.com/

Highlights from the PER® CME activity "The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Seth A. Wander, MD, PhD, Reshma L. Mahtani, DO, and Shanu Modi, MD, review pivotal data regarding the use of antibody-drug conjugates in the treatment of metastatic triple-negative breast cancer, and discuss how they apply these data in the management of their patients.Earn CME credit by completing the full accredited activity (available through July 31, 2027): https://www.gotoper.com/courses/the-adc-revolution-in-metastatic-breast-cancer-redefining-treatment-selection-and-sequencing-kpppThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

CDMX invierte más de 14 mmdp en educación básica  Continúa en Tepotzotlán el Programa Canje de Armas 2026Javier Milei suspende viaje al Reino Unido por tensión sobre MalvinasMás información en nuestro podcast  #grc

"It's really hard to justify a test that has any complications if there isn't any reasonable expectation of benefit," says Dr. Rita Redberg, who has spent her career trying to help fellow clinicians consider the actual value of routine screenings and diagnostic testing in asymptomatic patients. Dr. Redberg -- a cardiologist and professor of medicine at the University of California, San Francisco for more than three decades -- is one of the leading voices advocating for a “high-value care” approach, an uphill fight in a healthcare system that tends to reward action over restraint. Her highest profile effort was launching the instructive “Less is More” series in JAMA Internal Medicine when she served as its editor-in-chief for 14 years. On a related track, her research on the assessment of the safety and effectiveness of medical technology, specifically high-risk cardiovascular devices, has yielded a troubling picture. "We found only 1% of devices enter the market through the FDA's most rigorous approval process. The high-quality evidence to support benefit for these devices that I had assumed was present, wasn't actually there.” Join Raise the Line host Lindsey Smith for an eye-opening exploration of what Dr. Redberg considers to be the overlooked risks and false reassurance of common tests and procedures, and her efforts to put the “do no harm” principle of medicine at the forefront of everyday practice.Mentioned in this episode:UCSF School of MedicineJAMA Internal Medicine's Less is More Series If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Sandoz's recent move to invest $2.5 billion in creating a vertically integrated biosimilar manufacturing network is making waves across the industry. This significant investment underscores the growing importance of biosimilars as cost-effective alternatives to biologics. With plans to develop 100 biosimilars by 2040, Sandoz is strategically positioning itself to meet increasing global demand for affordable treatments. This initiative not only enhances their production capabilities but also aligns with the push from healthcare systems worldwide for more economical care options. The vertical integration model promises to streamline production, reduce supply chain issues, and maintain high-quality standards, reinforcing Sandoz's competitive position in the biosimilars market. Meanwhile, Amgen has achieved a noteworthy milestone with its drug Imdelltra (tarlatamab-dlle), which met its Phase 3 overall survival endpoint for extensive-stage small-cell lung cancer (SCLC) maintenance therapy. Imdelltra, a bispecific T-cell engager targeting DLL3, represents a novel approach in oncology, potentially setting a new standard of care for SCLC patients who have severely limited treatment options. The positive trial results could lead to regulatory approval, broadening access to this innovative therapy and potentially improving patient outcomes significantly. Regulatory stability is on the horizon with the FDA appointing permanent heads for its Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER). This leadership continuity is crucial as it supports the agency's ongoing restructuring efforts aimed at enhancing efficiency and oversight. Stable leadership within these centers ensures rigorous drug evaluation processes continue, which is critical for timely approvals and has a direct impact on drug developers' strategic planning and market entry timelines. Clinical trials continue to yield varied results, showcasing the inherent uncertainties in drug development. AstraZeneca's Tozorakimab showed promise with approximately a 30% reduction in exacerbations in Phase 3 trials for chronic obstructive pulmonary disease (COPD), hinting at improved management of respiratory diseases through targeted monoclonal antibody therapies. Conversely, challenges persist as Evommune's Evo756 did not meet its Phase 2b trial expectations for atopic dermatitis, and Tyra Biosciences' Dabogratinib fell short in non-muscle invasive bladder cancer trials—highlighting the unpredictable nature of clinical research. Investment flows into biopharmaceuticals remain robust, with Encoded Therapeutics raising $275 million to advance its gene therapy program for Dravet syndrome. Similarly, Luma Group has secured $410 million for ventures focusing on ophthalmology and cellular rejuvenation technologies. Such investments reflect strong confidence in gene and cell therapies' transformative potential on patient care. On the mergers and acquisitions front, Sernova Biotherapeutics' merger with Seraxis to form Betanova Biotherapeutics exemplifies how companies are consolidating expertise to enhance R&D capabilities and expand their market reach, particularly in cell therapy solutions for diabetes management. These strategic consolidations indicate ongoing efforts to leverage synergies that could redefine therapeutic landscapes. The biopharmaceutical sector is also seeing shifts due to ongoing geopolitical tensions between the U.S. and China, pushing companies to seek investment opportunities outside China. This diversification strategy aims to mitigate geopolitical risks while continuing global innovation efforts. In obesity treatment research, partnerships like those between GemPharmaTech signal new frontiers beyond GLP-1 receptor agonists. These collaborations highlight an industry commitment to tackling global health challenges with innovative therapies that prioritize efficacy and safety. These developments collectively paint a picture of a dynamic industry marked by scientific breakthroughs, strategic investments, regulatory evolution, and significant challenges in clinical trials. As these sectors evolve, they promise exciting advancements that could profoundly redefine global healthcare paradigms. The focus remains on overcoming therapeutic barriers through sustained research efforts and innovative approaches—a testament to the industry's relentless pursuit of improving patient care outcomes worldwide.Support the show

Como os novos imunobiológicos no controle da DPOC, as diretrizes emergenciais para suporte parenteral em neonatos e a medicina do estilo de vida ocupacional impactam a prática médica? Neste episódio do Afya News, analisamos os ensaios de fase 3 apresentados no congresso da European Respiratory Society e publicados no New England Journal of Medicine demonstrando que o tozorakimab, anticorpo experimental da AstraZeneca, reduziu em 30% as exacerbações da doença pulmonar obstrutiva crônica ao longo de um ano, inclusive em perfis de pacientes não contemplados por terapias biológicas recentes. Discutimos também a diretriz emergencial da FDA para a manipulação de nutrição parenteral inicial em recém-nascidos e prematuros diante de crises de desabastecimento industrial, destacando o rigor exigido em biossegurança e esterilidade. Por fim, apresentamos no Radar as novas orientações técnicas do CDC/NIOSH para a integração estruturada da medicina do estilo de vida à saúde ocupacional corporativa, com foco em prevenção cardiometabólica e saúde mental. O Afya News apresenta notícias da medicina com informação confiável e atualizada no seu tempo. Criado pela Afya, o maior hub de educação e soluções para a prática médica do Brasil, nosso propósito é transformar a saúde junto com quem tem a medicina como vocação.Fontes do episódio aqui:⁠https://portal.afya.com.br/podcasts/afya-news/10-09-2026Conteúdo 100% validado por equipe médica.Médico Responsável: Dr. Guilherme Rodrigues — CRM-RJ 1049461.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we unveil a series of transformative strides in drug approvals, clinical trials, and regulatory landscapes that are reshaping the future of patient care. AstraZeneca's camizestrant, now branded as Etcamah, has received FDA approval for treating ESR1-mutated hormone receptor-positive, HER2-negative advanced breast cancer. This approval is a testament to the potential of selective estrogen receptor degraders (SERDs) in oncology. The Phase 3 trial results highlight camizestrant's efficacy when combined with CDK4/6 inhibitors, offering a tailored therapeutic strategy for patients with ESR1 mutations. Such advancements in personalized oncology are steering the industry toward more precise treatment paradigms. Complementing this approval, Guardant Health's Guardant360 CDx has been sanctioned as a companion diagnostic tool for camizestrant. The liquid biopsy-based method precisely identifies ESR1 mutations, underscoring the growing reliance on precision diagnostics in cancer management. As precision medicine continues to evolve, integrating diagnostics with therapeutics becomes crucial in achieving optimal patient outcomes. Bristol Myers Squibb has made headlines with its CAR-T cell therapy, arlocabtagene autoleucel, showing efficacy in its Phase 3 trial for GPRC5D-targeted relapsed or refractory multiple myeloma. This advancement reflects the burgeoning application of cell-based treatments in hematological malignancies and signals a shift towards personalized immunotherapy strategies promising improved patient outcomes. On a related note, Brainchild Bio's significant $116 million fundraising initiative aims to advance CAR-T therapies tailored for childhood brain cancers. This development highlights the potential of CAR-T technology beyond hematologic cancers and indicates an intensified focus on pediatric oncology therapeutics. In regulatory news, Shionogi's cefiderocol has gained approval from Australia's Therapeutic Goods Administration (TGA) for combating carbapenem-resistant gram-negative bacterial infections. Cefiderocol addresses critical needs in combating multidrug-resistant pathogens, particularly in urinary tract infections, and highlights ongoing global efforts to tackle antimicrobial resistance. Clinical trials continue to yield promising outcomes. Pharvaris' deucrictibant showcased positive results in its Phase 3 trial for hereditary angioedema by effectively targeting the bradykinin B2 receptor. Novo Nordisk's semaglutide (Wegovy) demonstrated remarkable efficacy in reducing obesity among children during its Phase 3 trials. These results emphasize continued innovation in treating metabolic disorders and rare diseases by leveraging small molecule therapeutics and receptor modulators. Not all developments have been positive. Novartis and Ionis Pharmaceuticals faced setbacks with pelacarsen failing to meet endpoints in a Phase 3 trial aimed at reducing major cardiovascular events despite lowering lipoprotein(a). This underscores the challenges of translating promising biomarkers into effective therapeutic interventions. Regulatory challenges were also observed as American Regent recalled batches of epinephrine due to contamination issues, and Boston Scientific recalled spinal cord implants linked to serious injuries. These instances underscore the importance of stringent quality control and regulatory compliance to ensure patient safety. Meanwhile, Amgen's DLL3-targeted therapy, Imdelltra, achieved an overall survival win in a first-line setting for small cell lung cancer (SCLC), although specific numerical results were not disclosed. This bispecific antibody could set a new standard for early intervention in SCLC, emphasizing the potential of targeted therapies in improving survival rates for aggressive cancers. In other advancements, Roche continues to dominate neurology with top positions in corporate reputation rankings within this therapeutic area. This accolade reflects Roche's commitment to innovation and patient-centric approaches to managing neurological disorders. As these developments unfold across various domains of pharmaceutical innovation and regulation, they collectively signal a dynamic era for the industry marked by rapid scientific progress and evolving treatment strategies. The implications are profound, offering potential improvements in patient outcomes through more targeted therapies while highlighting challenges such as clinical trial failures that necessitate continued diligence in drug development strategies. As these trends unfold, they hold promise for significant advancements in treatment efficacy and safety across various therapeutic areas. Thank you for tuning into Pharma Daily. Stay informed about the latest industry developments as we continue to explore the dynamic landscape of pharmaceutical innovations together.Support the show

Children's mental health, prevention vs treatment, resilience, self-esteem, the CAMHS waiting list - Laura Earnshaw, Founder of myHappymind, on why we're solving children's mental health at the wrong end, and what teaching it early actually looks like.What if most children's mental health problems could be prevented years before they ever reach a waiting list? Steve Roest sits down with Laura Earnshaw, former Global Head of Talent at AstraZeneca, now Founder and CEO of myHappymind, the NHS-backed programme in over 2,000 schools. After her own son struggled at school and a family member was sectioned, Laura left her corporate career to build the skills she'd been teaching senior leaders for children as young as three.In this episode:Why children's mental health needs prevention, not just treatmentWhat myHappymind teaches children as young as threeThe 120% vs 20% data proving early intervention worksThe commissioner who wouldn't fund prevention and whyWhy "character, not competence" builds real self-esteemWhy founders should stop publicly blaming the NHSLaura's mottos for getting through the hard days0:00 Why we get children's mental health backwards 0:51 Intro 2:20 From AstraZeneca to founding myHappymind 5:44 The two moments that changed everything 8:04 A million kids waiting: prevention vs treatment 10:34 What you can teach a three-year-old 11:38 Character, not competence: building real self-esteem 15:54 The data - 120% vs 20% on school absence 19:12 The commissioner who wouldn't fund prevention 40:44 Why founders should stop blaming the NHS 42:42 How the NHS came to her first 50:05 "Everything is figureoutable"

2,6% Zinsen p.a. auf ein unbegrenztes Guthaben mit bis zu fünfmal der gesetzlichen Einlagensicherung*. Auch für Kinder. Das gibt's bei Scalable Capital. Mehr Infos hier. Tesla präsentiert Cybercab ungewohnt unspektakulär und lässt Fragen offen. UiPath und Asana leiden unter KI-Angst. Speicherchips boomen dank GPT-6. AstraZeneca bekommt Brustkrebs-Zulassung. Novartis scheitert mit Herz-Studie. Lululemon crasht. VW einigt sich. Coca-Cola (WKN: 850663) hat 50.000 Freestyle-Automaten, die in Echtzeit Daten nach Atlanta senden. So testet Coke neue Produkte und entdeckt Trends. Dirty Sodas und Mini-Maschinen für Hotels kommen gut an. Aber reicht das bei nem KGV von 26? Xiaomi (WKN: A2JNY1) verkauft ab 2027 E-Autos in Deutschland. Die Autosparte macht schon ein Viertel vom Umsatz. Aber das Handygeschäft bröckelt, weil Speicherchips Marge fressen. Diesen Podcast vom 07.09.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. *Veränderlicher Zins auf unbegrenztes Guthaben. Konditionen sowie Guthabenverteilung auf scalable.capital/tagesgeld. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Erik Haeffler, CEO at APL.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Erik, covering: Two decades at AstraZeneca, including being at the forefront of global sourcing and increasingly sophisticated supply chain management in pharma Managing a highly complex network of more than 100 CDMOs during his time at Meda Lessons from six years at Recipharm, where he led 4,000 people across 14 manufacturing sites The unique story behind APL, what attracted him to the CEO role, and how his assumptions about a state owned business were challenged Implementing a clear strategy for APL's CDMO business, leading to stronger differentiation and significant growth The decision to acquire a penicillin facility, and the growth engine now driving APL forward   Erik leads APL, a Swedish pharma manufacturing company of 600 people across 5 sites. Being a state owned enterprise with a public policy assignment, APL is a bit of an odd bird on the pharma market. The state assignment comprises pharmacy compounding for the Swedish market, where APL has approx. 80% market share, and also a formal preparedness mission for supply in times of crisis and war. APL is also a fully commercial CDMO with a wide range of capabilities, focusing on a segment that fits into the company's origin in compounding. Erik has more than 30 years in the pharma industry with senior roles in AstraZeneca, Meda and Recipharm. He is also a Board member at Nanologica.  Connect with him on LinkedIn.      Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!  

For millions of young women and girls, often the first place they turn with questions about their bodies isn't a doctor's office, it's social media which can lead to encountering many misconceptions and outright misinformation. Or, if the right voices show up, it can mean something else entirely. Our guest today, Dr. Charis Chambers, is one of those voices. She's a board-certified OB/GYN with specialty certification in Pediatric & Adolescent Gynecology, and Chief Medical Officer at Clue, a leading period and cycle-tracking app. She's also the founder of The Period Doctor, a platform she launched in 2019 to provide medically accurate reproductive health information and to place more minority physicians in the spaces where patients are already looking for answers. As she tells Raise the Line from Elsevier host Lindsey Smith, Dr. Chambers embraces the role of being a bridge between generations: "I can serve as a medical mediator where I advocate for the child and then educate the parent so that the child's concerns are met." Stay tuned to this important conversation to also learn about: Her new book, The Period and Puberty Parenting Revolution, which tackles many of the same myths she encounters every day in her clinic; Why stubborn myths around periods rarely hold up once you ask where they come from; How she thinks about the responsibility, and limits, of being a trusted medical voice on social media. Mentioned in this episode: Clue The Period Doctor The Period and Puberty Parenting Revolution If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Starting a biologic can feel intimidating, especially if you are worried it means being on medication forever, or wondering if it will actually replace your inhaler or your next sinus surgery. After this episode, we hope your biggest biologics questions are answered. Kortney and Dr. Payel Gupta are joined by Dr. Giselle Mosnaim, an allergist and immunologist, to walk through the united airway, what uncontrolled disease really means, and the most common questions patients have before starting a biologic. What we cover in this episode about biologics for asthma, COPD, and nasal polyps The united airway. Why the nose and lungs share the same lining, and why the same biologics can treat conditions in both. What a biologic actually is. How it targets one specific part of the immune system instead of suppressing the whole thing like steroids. What uncontrolled disease means. Why taking your medication as prescribed does not always mean your asthma, COPD, or nasal polyps are under control. The goal of starting a biologic. What results to expect, how biologics work alongside your inhaler or nasal spray instead of replacing it, and how they can reduce the need for repeat sinus surgery. Common myths and fears. Answers to real patient worries about weight gain, needles, side effects, pregnancy, and being on a biologic long term. ________ Made in partnership with The Allergy & Asthma Network. Thanks to AstraZeneca for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute for professional medical advice. Always consult with your healthcare provider for any medical concerns.  

This episode covers what matters most from ESC Congress 2026:  Heart failure (incl. cardiomyopathies) Primary and secondary prevention ACS & coronary intervention Host: Emer Joyce Guests: Davide Capodanno, Martha Gulati, John McMurray Want to watch that episode? Go to: https://esc365.escardio.org/event/2562   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Martha Gulati has declared to have potential conflicts of interest to report: Merck-Data Monitoring Committee for lipid lowering product. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. John McMurray has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Global Clinical Trial Partners Ltd., WCG Clinical Service, ARMGO Pharmaceuticals, At the Limits Ltd., Hilton Pharmaceuticals, River BioMedics, Novartis, Cytokinetics, Cardurion, Bayer AG, Chugai Pharma UK, Astra Zeneca, AnaCardio, Alnylam, Protherics Medicine Developments Ltd., DalCor Pharmaceuticals, Alkem Metabolics, Canadian Medical and Surgical Knowledge, IMEDIC Pharmaceuticals Micro Labs Ltd., Centrix Healthcare, Eris Lifesciences, Hikma Pharmacueticals, Imagica Health, Intas Pharmaceuticals, J.B. Chemicals & Pharmaceutical, Lupin Pharmaceuticals, Medscape/Heart Org., ProAdWise Communications, Radcliffe Cardiology, Sun Pharmaceuticals, translational medicine academy, Regeneron, MCI India, Emcure Pharmaceuticals, Biohaven Pharmaceuticals, Kirkland & Ellis Int. Ltd., Tangram Therapeutics, Alphasights Ltd., APTA Therapeutics, Zoll Pharmaceuticals, MSN Lab. Ltd., Omicuris PVT Ltd. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into groundbreaking scientific advancements, crucial regulatory updates, and strategic industry movements that are shaping the future of patient care and drug development. AstraZeneca, in collaboration with Daiichi Sankyo, has achieved a significant milestone with their antibody-drug conjugate, Enhertu, combined with Roche's Perjeta. This combination therapy has recently secured European Union approval for first-line treatment of HER2-positive metastatic breast cancer. The approval highlights the transformative potential of antibody-drug conjugates in treating aggressive breast cancer subtypes. Enhertu targets HER2-positive tumors by delivering cytotoxic agents directly to the cancer cells, thereby minimizing off-target effects and enhancing efficacy. Such innovations underscore the industry's commitment to improving therapeutic outcomes for patients facing complex medical challenges. In another notable development, Novartis has entered into a substantial $3.2 billion licensing agreement with Alteogen, focusing on ALT-B4 hyaluronidase technology. This collaboration emphasizes the growing interest in subcutaneous drug formulations that offer improved patient compliance and convenience compared to traditional intravenous routes. Hyaluronidase helps disperse and absorb subcutaneously injected drugs more efficiently by degrading hyaluronic acid in tissues, thereby enhancing bioavailability and reducing injection volumes. Shifting gears to clinical trial advancements, Hutchmed's combination therapy featuring Tagrisso (osimertinib) and Orpathys (savolitinib) has achieved a Phase 3 success in first-line treatment for MET-overexpressing non-small cell lung cancer. This marks an important stride towards personalized medicine approaches that target specific genetic mutations driving tumor growth. The success of this combination therapy points to a future where targeted treatments become more prevalent in addressing complex oncogenic drivers. In the realm of strategic partnerships, Novacyt and Illumina have embarked on a five-year collaboration focusing on diagnostics and DNA sequencing technologies. This partnership aims to leverage Illumina's genomic sequencing expertise to advance precision medicine efforts in diagnostics, further highlighting the importance of collaborations in overcoming technological hurdles. Meanwhile, in gene therapy developments, NewBiologix and Synastra Biotechnology have joined forces to develop stable recombinant adeno-associated viral cell lines for Duchenne muscular dystrophy therapies. Their partnership aims to address manufacturing challenges associated with gene therapies for rare diseases, potentially accelerating treatment availability for patients in need. Despite these promising advancements, the industry is not without its challenges. Cellares recently announced significant job cuts following the loss of a contract with Bristol Myers Squibb for cell therapy production. Additionally, regulatory scrutiny remains high as evidenced by the UK Medicines and Healthcare products Regulatory Agency's suspension of Amgen's Tavneos amid concerns over trial data integrity. Such developments underscore the critical importance of maintaining rigorous data standards in drug development. Turning our attention to regulatory dynamics, the Trump administration has introduced a new drug pricing model under Medicare, providing weight loss medications at reduced prices for eligible seniors. This initiative involves major players like Eli Lilly and Novo Nordisk and aims to enhance access to obesity treatments for seniors—a move that could signify a shift towards preventive healthcare. On the clinical front, Alnylam Pharmaceuticals' next-generation gene-silencing technology shows promise for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Despite setbacks faced by AstraZeneca and Ionis Pharmaceuticals in similar trials, Alnylam's approach holds potential when used alongside standard treatments. The pharmaceutical sector also sees evolving market dynamics with reverse mergers rising sharply by 1,600% in Q3. This trend rivals traditional IPOs as companies seek alternative routes to liquidity amid fluctuating investor sentiments. Such strategic adaptations reflect the industry's resilience amidst economic uncertainties. In conclusion, these developments paint a picture of an industry dynamically adapting to technological advancements, regulatory changes, and market demands. From innovative drug delivery technologies to strategic partnerships and robust regulatory frameworks, the sector remains committed to advancing precision medicine and improving patient care globally. As these trends continue to unfold, they promise significant implications for drug development processes and therapeutic paradigms across various disease landscapes.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The current landscape in the pharmaceutical and biotech industries is a tapestry of dynamic mergers, clinical trial advancements, regulatory approvals, and strategic partnerships. A major highlight is Eli Lilly's acquisition of Merida Biosciences for up to $2.9 billion. This move exemplifies the industry's strategic focus on expanding portfolios specifically in autoimmune and allergic diseases. Merida's precision degradation platform is set to significantly enhance Eli Lilly's capabilities, offering potential novel therapies that could address unmet needs in these therapeutic areas. Regulatory developments continue to shape the trajectory of this industry. The FDA's approval of Protagonist Therapeutics' Mimrylo (rusfertide) for polycythemia vera marks a significant advancement in peptide therapy. This hepcidin mimetic offers a novel approach to regulate hematocrit levels, addressing a critical need in managing this blood disorder. Additionally, the FDA has expanded PharmaEssentia's Besremi (ropeginterferon alfa-2b) label to include essential thrombocythemia regardless of genotype, broadening its applicability in myeloproliferative neoplasms. The approval of Stelara (ustekinumab) for pediatric patients with ulcerative colitis underscores an ongoing commitment to developing therapies for autoimmune conditions by utilizing monoclonal antibodies targeting IL-12/IL-23 pathways. Clinical trial outcomes continue to underscore the potential transformative impact of advanced therapeutics on patient care. Jazz Pharmaceuticals' Ziihera (zanidatamab) achieved a second overall survival win in a Phase 3 trial for HER2-positive gastroesophageal adenocarcinoma, reinforcing the promise of bispecific antibodies in oncology. In cardiovascular health, AstraZeneca's AZD5462, an oral relaxin agonist, demonstrated promise in a Phase 2 trial for chronic heart failure, showcasing the potential of small molecule therapeutics in this field. Additionally, Arrowhead Pharmaceuticals' Redemplo (plozasiran) Phase 3 data supports label expansion efforts for severe hypertriglyceridemia through RNA interference technology targeting the ApoC3 gene. The industry also continues to witness promising partnerships aimed at leveraging cutting-edge technologies. Mission Therapeutics and Neurolight are collaborating to deploy brain function biomarkers in Parkinson's disease trials, linking diagnostics and digital health innovations. Meanwhile, Create Medicines and Westgene Biopharma are advancing in vivo CAR therapies using targeted lipid nanoparticle delivery technology—a significant step forward in cell and gene therapy. Despite these positive developments, challenges persist. BioNTech's halt of its Phase 2 trial of an mRNA vaccine for colorectal cancer due to futility highlights the inherent uncertainties in drug development, particularly within innovative domains like personalized neoantigen therapies. Financial strategies remain pivotal as companies like Electra Therapeutics file IPOs to advance their immunology and cancer pipeline assets, indicating robust investor interest in these high-potential areas. Quoin Pharmaceuticals' planned $50 million private placement signifies strategic capital infusion towards rare and orphan disease development. In terms of sustainability, efforts within healthcare are gaining momentum as organizations like UCI Health and Kaiser Permanente explore electrification as part of their environmental agendas. These initiatives reflect a broader trend towards reducing healthcare's carbon footprint, highlighting the sector's role in addressing climate change. Finally, regulatory landscapes continue to evolve with legal challenges as Florida's Attorney General sues Express Scripts and Prime Therapeutics over alleged price-fixing. This lawsuit underscores ongoing scrutiny over pharmacy benefit managers' practices, potentially prompting regulatory reforms to ensure fair pricing mechanisms within the pharmaceutical supply chain. Overall, these developments illustrate a dynamic landscape where scientific innovation and regulatory maneuvers intersect to shape future pharmaceutical and biotech trajectories. The implications for patient care are profound as new treatments offer hope while industry players navigate complex regulatory and market environments. As these trends continue to unfold, they hold significant implications for future drug development processes and healthcare solutions worldwide. Thank you for tuning into Pharma Daily; we'll continue to bring you critical insights into this ever-evolving industry.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore groundbreaking advancements, regulatory updates, and strategic partnerships shaping the future of patient care and drug development. Revolution Medicines has achieved a significant milestone with the FDA approval of its RAS inhibitor, daraxonrasib, for metastatic pancreatic cancer treatment. This approval follows an impressive presentation at the American Society of Clinical Oncology meeting that garnered widespread acclaim. Targeting one of the most challenging cancers, this advancement offers renewed hope for patients with limited treatment options and sets a potential new standard in pancreatic cancer therapy. In another promising development, Amgen and AstraZeneca have successfully completed a Phase 3 trial for their drug Tezspire in eosinophilic esophagitis. This success positions Tezspire as a formidable contender in the competitive landscape of inflammatory disease treatments, directly challenging Sanofi and Regeneron's Dupixent. The focus on biologics targeting specific inflammatory pathways underscores ongoing innovation in this area, offering enhanced treatment options for patients. On the regulatory front, the FDA has expanded its authorization for Tivicay, an HIV medication, to include newborns. This move aligns with global efforts to advance pediatric HIV treatment and address public health challenges. Additionally, Roche has secured further FDA approval for diagnostic tests linked to Jazz Pharmaceuticals' oncology drug Ziihera, emphasizing the critical role of companion diagnostics in personalized medicine. Meanwhile, strategic initiatives are also taking shape in pricing agreements. The Trump administration is preparing to announce "most favored nation" pricing agreements with mid-sized biopharma companies as part of ongoing efforts to tackle drug pricing issues. Although these arrangements could lead to lower drug prices, they may also face industry resistance due to potential impacts on revenue. Flagship Pioneering's Profound Therapeutics has partnered with the Gates Foundation in a $35 million effort to discover new drug targets for preeclampsia—a dangerous pregnancy complication. Such collaborations are vital in accelerating research and offering innovative solutions to complex health problems. Artis Biosolutions is expanding its synthetic DNA and mRNA production capabilities with a new facility in Spain. This development highlights the growing importance of genetic medicines and reflects an industry shift towards next-generation therapies like gene editing and RNA-based treatments. On a global scale, CEPI is supporting Minapharm's Ebola vaccine candidate advancement into clinical trials amid a growing outbreak. This initiative is part of a broader strategy to enhance epidemic preparedness through rapid vaccine development and deployment. Another significant move comes from McKesson's $2.25 billion acquisition of Precision Medicine Group. This acquisition aims to strengthen McKesson's oncology and biopharma segments, emphasizing precision medicine's growing role in personalized cancer treatment. In the context of geopolitical dynamics, concerns about Chinese dominance in clinical trials and supply chains have been raised by Congressman Nathaniel Moran. This highlights strategic dependencies and underscores the need for robust domestic capabilities in biopharmaceutical research and manufacturing. In clinical developments, Bausch + Lomb faced setbacks with its phase 2 trial combining dry-eye disease drugs Xiidra and Miebo but remains optimistic as it advances to phase 3 trials. Conversely, Spyre Therapeutics is deprioritizing its anti-TL1A antibody approach following underwhelming phase 2 results for rheumatoid arthritis—a testament to the rigorous validation process required before new therapies can reach patients. Akeso's success with its PD-1xVEGF bispecific antibody ivonescimab in biliary tract cancer demonstrates innovative biologics' potential to expand treatment options beyond traditional indications. In regulatory news concerning Capricor Therapeutics' Duchenne muscular dystrophy therapy, an extended FDA review period reflects careful regulatory evaluation following additional data submissions. These developments paint a picture of a dynamic landscape where scientific innovation is paralleled by regulatory challenges and strategic partnerships aimed at addressing both market demands and pressing health issues. The continued focus on personalized medicine, competitive dynamics in biologics, and global collaboration efforts underscores a transformative period for pharmaceuticals and biotech industries. As these sectors evolve, they hold the promise of delivering more effective treatments worldwide while addressing unmet medical needs across various domains.Support the show

"I'd already finished my cardiovascular unit. I'd finished my pulmonary unit. I had never heard about this in any of my classes." That was Dr. Joel Bervell's reaction to discovering that a device used every day in hospitals -- the pulse oximeter -- reads less accurately on darker skin tones. He posted a 30-second video about this consequential discrepancy that, to his utter surprise, gained over 500,000 views by the next morning. That video launched Dr. Bervell into orbit as a social media presence and created his identity as The Medical Mythbuster. In just a few years, he's built a following of two million people, earned a Peabody Award and was named to the inaugural Time 100 Creators list, all while finishing his residency.  On this episode of Raise the Line, host Lindsey Smith welcomes Dr. Bervell to explore the roots of this kind of bias and the real world impact of drawing attention to it. “The most impactful biases in medicine exist because no one stops to ask who was included in the original data and who was left out,” Dr. Bervell explains. Stay tuned to also learn about: His YouTube animated series The Doctor is In which helps kids understand how their bodies work, as well as providing medical role models; How to build trust with marginalized communities; His forthcoming book, The Default Body which examines who medicine was actually designed for. Mentioned in this episode:Dr. Bervell on InstagramTikTok ChannelFacebook"The Doctor Is In" Show If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Needing oral steroids for your asthma is a signal, not just a setback. It could be a sign that your asthma is not actually under control, even if you feel like you're managing it day to day. Dr. Wes Sublett joins us to talk about why relying on steroid bursts is a warning sign, not a solution. Dr. Sublett breaks down what actually counts as an asthma exacerbation, the real risks of frequent oral steroid use, and the treatment options available so patients can avoid repeat trips to the ER. What we cover in this episode about oral steroids and asthma control Steroid bursts as a warning sign. Needing oral steroids for asthma is a signal your maintenance treatment may not be working. What actually counts as an exacerbation. Dr. Sublett explains the difference between a flare and a true asthma exacerbation, and why that distinction matters. The real risks of oral steroids. Repeated courses are linked to bone loss, diabetes, cataracts, and other long-term health risks. Why your specialist doesn't automatically know. ERs and urgent cares don't notify your asthma specialist when you're treated, so you have to share that history. Treatment options beyond steroid bursts. Triple therapy and biologics can reduce or eliminate the need for oral steroids for many patients. More resources Oral Corticosteroids (OCS) for Asthma, a deeper explainer from Allergy & Asthma Network What if I Can't Afford My Asthma Medication? ________ Made in partnership with The Allergy & Asthma Network. Thanks to AstraZeneca for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute for professio

For decades, the rescue inhaler was simple: feel tight, take a puff, breathe easier. But the newest asthma guidelines have changed what's actually recommended inside that inhaler, shifting away from plain albuterol toward a combination inhaler that treats symptoms and inflammation at the same time. Kortney and Dr. Payel Gupta are joined by Dr. Bill McCann, allergist and CEO of Allergy Partners, to break down why this combo inhaler approach is now preferred, what it actually contains, and why auto-refilling your old rescue inhaler might be working against you. What we cover in this episode about rescue inhalers Understanding asthma: the boiling pot analogy. Dr. McCann explains asthma inflammation using a pot of water on the stove, and why a bronchodilator alone never turns down the heat. Why a combo inhaler is now preferred. The newest guidelines recommend a single inhaler containing both a fast-acting bronchodilator and a low dose of anti-inflammatory steroid. AIR and MART, explained simply. Two ways doctors are using this combo inhaler: either as-needed only, or as a daily plus as-needed routine. The myth of "mild" asthma. Why intermittent or infrequent symptoms don't mean you're free from risk. The auto-refill trap. Why an automatic pharmacy refill on your old rescue inhaler can quietly hide worsening asthma control from your doctor. More resources GINA 2026 Strategy Report (official source) What is asthma? Listen to the BATURA Trial ________ Made in partnership with The Allergy & Asthma Network. Thanks to AstraZeneca for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute for professio

Despite gains in recent years, Black, Hispanic, and Asian communities are still under-represented in the U.S. nursing workforce. We're going to explore that gap and how to close it on this episode of Raise the Line from Elsevier with Dr. Ernest Grant, Vice Dean for Diversity, Equity, Inclusion and Belonging at the Duke University School of Nursing. "You get a patient who is more compliant when they see someone who looks like them, who is from their culture and who can advocate on their behalf," he tells host Lindsey Smith.  Dr. Grant bases that and other insights on a rich professional background that includes 50 years in nursing, being a leading advocate for his profession and breaking down barriers himself as a male nurse of color and the first man elected president of the American Nurses Association.  In this thoughtful conversation, Dr. Grant reflects on what it took to earn credibility in leadership roles, how he's navigating the political climate on DEI initiatives, and the causes and solutions to the persistent shortage in nursing faculty, among other pressing issues. Tune in for a uniquely-informed look at what it will take to build a stronger, more representative nursing profession. Mentioned in this episode: Duke University School of Nursing American Nurses Association If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Don’t miss this massive channel shift! Subscribe to our Newsletter:https://theultimatepartner.com/ebook-subscribe/ Check Out UPX:https://theultimatepartner.com/experience/ In this episode of the Ultimate Partner Podcast, host Vince Menzione sits down with Alexandra Zagury, Corporate Vice President of Channels at Microsoft, to explore ecosystem shifts, partner-led growth, and AI transformation. https://youtu.be/9jrSGX5bM90 Key Takeaways Microsoft’s telemetry and propensity data offer unprecedented insights that many partners are currently failing to unlock. Partners must evolve past basic licensing models and build comprehensive managed service stacks across the entire customer lifecycle. Establishing an AI Center of Excellence on the Microsoft platform is critical for capturing future market share and technical intensity. The modern tech ecosystem demands a shift from product-led growth to true partner-led growth driven by multi-partner collaboration. Renewal engines targeting 110% to 125% retention require an always-on motion starting well in advance of contract expiration. Investing in sales readiness and precision velocity training ensures that end sellers can effectively articulate the value of the Microsoft platform. If you're ready to lead through change, elevate your business, and achieve extraordinary outcomes through the power of partnership—this is your community. At Ultimate Partner® we want leaders like you to join us in the Ultimate Partner Experience – where transformation begins. Key Tags Microsoft, telemetry, Hyperscalers, channel, small medium enterprise, telcos, hosters, SSPs, Cisco, CSP, agentic GTM, propensity data, SPX, PUPP, cloud descent, MSPs, managed XDR, Agent 365, skilling, co-sell, renewals, flywheel, AI Center of Excellence, enterprise Transcript Alexandra Zagury Audio Podcast [00:00:00] Alexandra Zagury: One of the things that I think is the best kept secret at Microsoft is the telemetry that we offer our partners. [00:00:08] Vince Menzione: You can feel it happening. The ecosystem is shifting beneath us, the way Hyperscalers are partnering, how AI is remaking the channel and what it means to win in 2026. Welcome to the Ultimate Partner Podcast. [00:00:22] Vince Menzione: I’m Vince Menzi, own your host, and each week I sit down with leaders at the intersection of technology. Partnerships and outcomes. The voices shaping how ecosystems actually work. We talk about what’s real, what’s changing, and what it takes to lead in this era where the partner channel isn’t just part of the strategy. [00:00:41] Vince Menzione: It is the strategy because being in the room changes everything. Let’s [00:00:46] Guest: start. [00:00:50] Vince Menzione: I am thrilled because I get to have a leader that is somewhat new in role and is the corporate vice president of channels for Microsoft. And so Alex is here to, is joining us for the first time at Ultimate Partner. I’m thrilled to have you. Thank, thank you so much. Thank you so much. Welcome, welcome. [00:01:14] Vince Menzione: Thank you. Thank you. You and I are gonna be in the center seat in the middle. Okay. Yeah. Yeah. We wanna. So I am thrilled. Um, you’re relatively new in your role at Microsoft. [00:01:24] Alexandra Zagury: Seven months. [00:01:25] Vince Menzione: Seven months, [00:01:26] Alexandra Zagury: yes. [00:01:26] Vince Menzione: Wow. That’s a, that’s a crazy. So take us through, ’cause for those who don’t know you, but a little bit of an introduction, your title, your role, CVP, and uh, your remit. [00:01:37] Vince Menzione: Let’s talk about that and what your organization is focused in, in your mission. Yeah. [00:01:41] Alexandra Zagury: So hi everybody. Really exciting to be here. Thanks for the invitation, Vince. I always love to be with partners and with the channel. So my, I came to Microsoft to lead a new role, which we call Global Channel Sales, and it was part of the strategy of Microsoft to really bet on the growth in small, medium enterprise. [00:02:04] Alexandra Zagury: With the channel partner led growth. So my remit is really to lead our managed partners, but also to lead the strategy when it comes to the channel. Very specifically looking at the telcos, the distributors, the hosters. The sis and, uh, the SSPs of course. And, and so my role can be summarized in one word growth, and that’s what we do every single day is map our ambition to your ambition and figure out how we actually conquer this age of ai. [00:02:40] Vince Menzione: It’s a pretty big role. It’s a pretty, you know, I forgot about hosts ’cause we don’t, we don’t talk about them as much these days in the cloud. [00:02:48] Alexandra Zagury: Still a lot [00:02:48] Vince Menzione: of opportunity. You’ve got, and you’ve got all the telcos as well, which are pretty significant organizations, right? Lumen Field, just around the corner. [00:02:56] Vince Menzione: Mm-hmm. Right up the. Right up, I said across the river, but it’s across the pond in Seattle. And, uh, what does that look like from an organization perspective in terms of dollars? Are you allowed to disclose numbers? [00:03:08] Alexandra Zagury: No, we [00:03:08] Vince Menzione: don’t talk numbers. Okay. And, but you have a long career in this type of environment, in this role. [00:03:15] Vince Menzione: 10 years at Cisco, right? [00:03:17] Alexandra Zagury: Mm-hmm. [00:03:17] Vince Menzione: Tell us a little bit more about your background, [00:03:18] Alexandra Zagury: please. Yeah, sure. Um, well I started out as a, a sales leader. Uh, actually I started out in banking, if you wanna go all the way back. Um, but I fell in love with the channel actually, when I was at Yahoo, believe it or not. Wow. [00:03:32] Alexandra Zagury: Because it was the first interact sales model that I had the privilege to operate in, and I really understood. Stood the power of going through a channel. And then I was at Blackberry where I, I, I also, um, well had various sales leadership roles, but our model was all through, was all through the channel. [00:03:51] Alexandra Zagury: Yes. Um, some startups and then help [00:03:54] Vince Menzione: in those days too, right? [00:03:55] Alexandra Zagury: Yeah. It was all sps and I learned from Jim Balze the channel fundamentals. So, um, and then ended up, of course, at Cisco the last. Nearly 11 years, which I think is also one of the greatest channel companies. Yes. And really has thrived in a partner, partner led growth, and in a partner led model. [00:04:12] Alexandra Zagury: And so when, when Microsoft called, I mean, this was just the opportunity of a lifetime. To lead the channel during an era where we’re all getting disrupted, we’re all having to blueprint new systems, new ways of working, where go to market is getting identified, and we’re all having to figure out how to become customer zero ourselves, but then also how to go to market. [00:04:36] Alexandra Zagury: With, with agents. And so this was the, the most exciting time that I could think of to join the Microsoft ecosystem and really take us to the next level. [00:04:44] Vince Menzione: Well, your background is perfect for this. I, I, Rodney Clark is a friend, has been a guest on the podcast and in, in the studio, and I think of Cisco is the quintessential channel company. [00:04:56] Vince Menzione: Like when I think about how channel got created and how it worked well, it was always Cisco that did it. So give us like your perspective now, like seven plus months and like how does this feel like you’ve You’ve got a big remit and, uh, various, uh, routes to market. We’ll call them, uh, channels to market. [00:05:14] Vince Menzione: So take us through a little bit of that, like Yeah, sure. [00:05:16] Alexandra Zagury: Describe [00:05:16] Vince Menzione: the transition, what it’s been like [00:05:18] Alexandra Zagury: for you. So one of the things we’re focused on is supporting the channel through the transformation, and we look at it in a couple of lenses. The first lens is really helping the channel become customer zero. [00:05:29] Alexandra Zagury: We really believe that the partners that invest in. Actually identifying their own processes and their own go go to market are the channels, are are the partners that it can actually win because if you are using it, you’re gonna be able to sell it. The second layer is all about technical intensity, and I’m very passionate about this because I see it from two lenses. [00:05:51] Alexandra Zagury: One is. I would like each and every of our partners to lead in building an AI Center of Excellence based on the Microsoft platform. It is a unique opportunity. I can give you lots of numbers, right? We’ve all heard about the trillions of agents that are gonna be here by 2030. We’ve all heard about the tam. [00:06:12] Alexandra Zagury: I mean, our TAM is going from 777. Million to over a billion, uh, to over a trillion. I, it’s, the numbers are just enormous, insane, right? Over half a billion of customers in our base that are using, that are, that are based already on the Microsoft platform. So all the goodness of our IU IQ platform can be unlocked with all the services that the partners can build. [00:06:36] Alexandra Zagury: So investing in that technical skilling and building those practices are gonna be, is gonna be essential. The third part. The third pillar is all about ag agentic, GTM. So once you’re actually using, uh, the Microsoft platform, you’re gonna have to reimagine all your business’s pro processes, your sales processes, and the more that you are integrated into how we do, how we do things. [00:07:00] Alexandra Zagury: One of the things that I think is the best kept secret at Microsoft is the telemetry that we offer our partners. Yeah. I mean, it’s unbelievable. I’ve never seen the quality of propensity data. And now I’m gonna give you the ABCs, which is please, A SPX, which is where we get all our copilot data, PUPP, which is our proposal upsell, uh, planner, right, cloud descent, where you can actually get your next action directly to your sellers. [00:07:27] Alexandra Zagury: There is just so much goodness that we give, which is part of our, our investment in partners. Which takes me to the fourth pillar, and that is all about value alignment and one of the things that I’m very focused and I bring with me from, from Cisco and the work that I did with MSPs is really thinking through what is that value exchange between us and the partner. [00:07:49] Alexandra Zagury: I believe that I’m in the business of earning your trust. Earning your preference. And, and, and we do that by really mapping that value alignment. So not just, one of the things that the whole industry has copied from Microsoft is really looking at our incentives across the customer lifecycle. Yes. So really mapping the value alignment across the customer lifecycle, not just at the point of the deal. [00:08:13] Alexandra Zagury: ’cause that was the whole purpose of CSP. That’s right. The investments we make in tele telemetry, the investments we make in our go-to-market assets and having those bi-directional feedback loops so that we can be continuously improving. So those are sort of the things that I’m thinking about every day. [00:08:29] Alexandra Zagury: There’s a couple of others as we lead and support you in this transformation. ’cause I think of my job as to supporting and driving growth with you so that we have that joint ambition. But also supporting the transformation that both of us are on this journey. [00:08:44] Vince Menzione: And Microsoft was the first with Jay McBain was with us yesterday, and we talked, we’ve talked about this before, but you were the first company to take and look, get rid of the old metal systems, right? [00:08:55] Vince Menzione: The bronze, silver, gold, mm-hmm. And move to basically a point system for partners so that they can come at it from a kind of a global perspective on how they drive success. What was, um, what did you learn about this partner community, your first months that you didn’t expect? [00:09:12] Alexandra Zagury: Can I say something controversial? [00:09:14] Vince Menzione: Absolutely. Okay. [00:09:14] Alexandra Zagury: I love, [00:09:14] Vince Menzione: we love controversial, [00:09:15] Alexandra Zagury: so I think one of the things that I was surprised was that I didn’t see all the partners really unlocking the value of CSP. Yeah. What do I mean by that? When Microsoft moved to the Point System, and I was on the other side, really, I was so jealous of CSP when I was running managed services. [00:09:34] Alexandra Zagury: Here’s an offer that is for partners, for Partner that gives you that initial. Guarantee in terms of the margin that helps you throughout the customer life cycle with all the incentives and, and programs that we have. And I didn’t see, I mean there are some partners, but I was surprised not seeing more partners really building their value stack and their services across the lifecycle. [00:09:59] Alexandra Zagury: And I think there’s such a great opportunity now to do that. That was one of the most surprising things I thought. Oh my gosh, there must be so many, so many services stack, so many people really unlocking, unlocking that, that value. That was a, that was a little bit surprising. [00:10:14] Vince Menzione: Why? Why do you suppose, why do you suppose that was happening? [00:10:17] Alexandra Zagury: I think some of the things that we were listening here, there’s some, sometimes complexity. There are things that we still have to. Get better on, and I’m one of the first ones to say that like our partner experience, we have, um, you know, a lot of focus right now on partner center and ensuring that we’re identifying it. [00:10:36] Alexandra Zagury: I don’t know if I can say it, but, you know, one of the things that we’re looking at is replicating internally. We have Agent J. That supports our sellers through the sales process. Nice. We’re looking at having something similar for our partners. Very cool. Getting some claps there. So, yeah, so, uh, I think, you know, that I, some, there are some lockers that we, we have to acknowledge a lot of them are operational and comes with being a 50-year-old company. [00:11:02] Vince Menzione: I, I’ll give you my perspective too. I wanna get your thoughts on this. ’cause I got to, I’ve gotten to know this MSP community, which is a, you mentioned managed services and that, um, I think that some of them, well, I think Microsoft is leaning in, in a much bigger way. Um, we had Jose on stage yesterday and just the, the energy around the room, there he is, he’s back here. [00:11:23] Vince Menzione: The energy in the room around the MSP community is palpable and it maybe it wasn’t there a few years ago. Maybe some people got off the bus, so to speak, like they weren’t really paying attention mm-hmm. To all the change and all the investments. That you men, you’re mentioning or being made to support this, would you, what would you say about that? [00:11:42] Alexandra Zagury: Yeah, I’d say that that that is correct, but I’d also say that what I learned, you know, leading MSP at Cisco was that. All the stars have to be aligned, right? And if one thing is not right, if you don’t have product market fit, if you, if you, if you don’t have a good way to, uh, consolidate your offer, if you don’t have that investment in practice development, like there’s a series of things that we need to get right. [00:12:07] Alexandra Zagury: And I think Jose and I spent a lot of time thinking through those things and we’re, we’re ready to, to welcome the community and specifically around security. I mean, that was the second thing that I was really surprised because I lost so many deals on the other side to Microsoft, and I was like, and then I come on this side and I’m like, there’s all this opportunity everywhere. [00:12:28] Alexandra Zagury: I look underneath this chair, this opportunity, and I’m like, why are people not going after it? There is the opportunity to build managed XDR solutions, the opportunity to reinvent the song. There’s, there’s just so much opportunity and I think people get so stuck in the. Just thinking of it from a licensing model and not thinking it from the, the full on end-to-end value that you can then unlock through the best licensing model on the planet. [00:12:55] Alexandra Zagury: And so, look, we’re here, we’re, we’re ready to talk to all of you and, and really figure this out ’cause we are gonna place really bet big bets next year on ensuring that we’re growing with the MSP community. [00:13:08] Vince Menzione: So what are you personally focused on in changing Microsoft to drive this. [00:13:13] Alexandra Zagury: Well, uh, I don’t know. [00:13:14] Alexandra Zagury: Changing is a, is a, is a big word. Well, I like evolution, change, [00:13:17] Vince Menzione: evolution, evolving. [00:13:18] Alexandra Zagury: You know, I [00:13:19] Vince Menzione: transition. [00:13:21] Alexandra Zagury: I think there is, there is a couple of things that I’ll say that one of the things that I, I’m really focused on right now, the first one is skilling. We’re at a time of such transformation. That investing in skilling, and if you look at our skilling model, it has four pillars. [00:13:37] Alexandra Zagury: The first pillar we’re best in class, in which is certification specializations, and making sure that our ecosystem is certified to go to market. The second one, which we call project ready. It’s sort of how we help you, uh, technically skill the folks that sit in your practices. And there’s more work to do there, and there’s more that you can learn about how we can actually help you. [00:13:59] Alexandra Zagury: And then the middle part I’m obsessed with right now, which is sales ready and tech sales ready. So it is ensuring, because AI is new for everybody. Yes. It’s a muscle, it is a proposition that you have to sell it’s value that you’re selling. I, I love what the gentleman from Lenovo was talking about. It’s, it’s that CSB always on motion. [00:14:21] Alexandra Zagury: Yes. And so really getting very crisp to the end seller at the, at the reseller. For example, at the end, seller at the partner about why Microsoft. Why now, how do I sell and how do I win? And giving them the assets, the competitive battle cards, the, the, the ability to end objection handling all these. Great, we have them. [00:14:45] Alexandra Zagury: I mean, the amount of content we have, but it’s about doing it at what I call precision velocity. [00:14:51] Vince Menzione: Precision [00:14:51] Alexandra Zagury: velocity, right? Which is this concept of how do we get very precise at a persona level. So that we get the velocity of impact. And so I’m, I’m very obsessed with that right now. And there’s two other things I’m very obsessed with, right? [00:15:04] Alexandra Zagury: The other one is this practice building, ensuring that we are together building these AI centers of excellence, um, especially for all our managed partners. This is something that I’ve put on, uh, every single PDM in our org is gonna, is gonna be talking about that. And then the third one is one that I find super interesting, which I think all of us. [00:15:25] Alexandra Zagury: Have a lot of work to do, which is partner to partner. [00:15:29] Vince Menzione: Yes. [00:15:29] Alexandra Zagury: If we look at a customer outcome, thank you. A customer outcome is built of many partners, right? There’s so many different touch points. I think some folks talk about seven partners in, in a customer outcome, and so how do we actually. Use agents, use agent solutions to suddenly unlock this opportunity because most of the time you’ll see an SSP with an si, maybe an ISV in the middle of a transaction to deliver on that customer outcome. [00:16:04] Alexandra Zagury: Yes. So what can we Microsoft do? And I’d love ideas, right? I haven’t cracked this. I don’t think the industry has completely cracked this. It’s more of a, a science than, than, well, more of an art than it is a science today. So that’s the third thing that I, I, I’d love to really improve and, and get better at. [00:16:20] Vince Menzione: I wish you got to see my slide earlier. ’cause I had the seven seats. I had this, I had the seven partners surrounding the customer. Customer is able to make their decisions now because with their cloud commitments [00:16:31] Alexandra Zagury: mm-hmm. [00:16:32] Vince Menzione: They’re in the, they’re in the seat where it used to be. I would rely on the partner to tell me what to do. [00:16:38] Vince Menzione: I, I’m cobbling together the best solution for my organization. Based on the trusted partners, to your point, those seven seats, and that’s partner to partner action. And Jay McBain was here yesterday and he took us through a great example. It’s AstraZeneca, that Microsoft won AWS, thought they were gonna win the deal, and then there were Microsoft partners in involved. [00:17:00] Vince Menzione: And the, the decision was made in December, but the deal didn’t happen until July. And that whole process was because all these different partners showed up. And influence the decision and the solution areas for that customer. [00:17:12] Alexandra Zagury: Yeah, that’s the best example of PLG partner led growth in action, which I think, again, that is the other thing that I’m super excited about is that actually p proving in the AI era that it’s about PLG as partner led growth, not the other PLGI. [00:17:31] Vince Menzione: I love that. I love that. Instead of product led growth, it’s partner led growth. So I understand there’s three layers that you’re very interested in that you want, you were gonna take us through today. Okay. Do you know about this, [00:17:44] Alexandra Zagury: the layers [00:17:45] Vince Menzione: of we have, uh, copilot chat. Oh, yes. 365 and, and agents. [00:17:49] Alexandra Zagury: Yeah. [00:17:50] Vince Menzione: From a product perspective, I thought maybe, [00:17:51] Alexandra Zagury: yeah, sure. [00:17:52] Alexandra Zagury: This is, I mean. This is the, uh, advantage of choosing the market Microsoft platform. Yeah, so as you look, look at it, there’s, there’s definitely different options, but when you look at Microsoft, what’s really, really interesting is that we have all the, all the layers. There’s no AI without data, and we’ve got that data foundation. [00:18:15] Alexandra Zagury: We also have the intelligence data foundation, right? Then we’ve got the, the layer of actually building those AI agents, and then the last layer that we have is actually the experience or the application layer. So when you look at our platform is a completely integrated platform with the different choices. [00:18:35] Alexandra Zagury: We are not behold, beholden to one LLM or another LLM. You’re actually able to bring your data and, and bring the LLM that you want to deliver on the, on the outcomes that you need. And I think that is very, very unique about our proposition. Yeah, I [00:18:50] Vince Menzione: agree. [00:18:50] Alexandra Zagury: But the other thing that is unique, it’s the most exciting product out there. [00:18:55] Alexandra Zagury: Agent 3, 6 5, our own oh oh seven. It really is a differentiated proposition that every single partner can build services around. Starting with your advisory services, tell me customer, what is it that you are thinking of? Then you actually move on to thinking about security because again, just like there’s no AI without data, you have to start with that data foundation. [00:19:24] Alexandra Zagury: There’s no AI without security and no security without ai. And so really thinking through how, uh, agent 3, 6, 5, I love it. I get these claps once a, I love, love really thinking about how Agent 3, 6 5 really unlocks, not only. A security budget, but an observability budget because you can do both. You are talking to both, uh, folks at the customer, right? [00:19:47] Alexandra Zagury: You can actually start talking about how you’re gonna actually govern all of these agents, manage all of these agents, but also there’s the observability layer, which is gonna tell you what actually can you do? How can you actually deliver on the outcomes that we all want from ai, which is productivity. [00:20:05] Alexandra Zagury: Experience and efficiency and all the other things. So I think this is the biggest opportunity this channel has ever seen, and every single partner is gonna have to make a choice on what platform they’re gonna lead with, and we believe it should be ours because it is completely integrated across these three layers with our very own oh oh seven. [00:20:30] Vince Menzione: I wanna get your perspective, but it feels like many of these partners in the MSP community are stuck at that CSP level. We were having this conversation about getting through that, coaching ’em through it. What would your be your perspective on that? [00:20:44] Alexandra Zagury: Um, I’d say, uh, use this moment to unlock that opportunity. [00:20:50] Alexandra Zagury: First off, invest in your skills. Get your, get your team skilled and, uh, on Microsoft, build your center of excellence. Map out your strategy where actually you’re gonna monetize and use all the different assets that we have. And if you are being really, um, I mean, most of them are serviced through a distributor. [00:21:12] Alexandra Zagury: Make your distributor accountable for supporting you in packaging the offers and giving you the, uh, information that you need in terms of skilling. And then in terms of co-selling, again, distributor has a lot of tools that can help you understand how to unlock the co unlock, the co-selling opportunity with Microsoft. [00:21:35] Alexandra Zagury: I think that’s another really big competitive advantage that Microsoft has. When, uh, Microsoft changed what it started by, by, by changing its strategy. I think clarity is kindness. We were very, very clear that where we want, we wanted partners, of course, to play an enterprise with a services stack, but we were very clear that we were betting on a partner led growth in small, medium enterprise, right? [00:22:03] Alexandra Zagury: And so we’ve built our whole operating system. Around that. And so I think it’s really about finding the information that you know you want, planning your strategy, getting skilled and go to market with us. Our co-sell Advantage is very, very unique. It is one of the only companies that has the sales teams completely aligned because CSP is our hero motion. [00:22:29] Vince Menzione: So being with a customer through the journey on CSP, but also renewals are a big component of growth. Talk to us about that. [00:22:36] Alexandra Zagury: Yeah. Renewals are, uh, a machine and an engine that is just absolutely beautiful. It’s your [00:22:42] Vince Menzione: flywheel. [00:22:43] Alexandra Zagury: It is your flywheel. Um, and it is the gift that keeps on giving. We, of course, have a very focused, um, and in fact, one of the things that I’ve done since. [00:22:52] Alexandra Zagury: Uh, since we’ve started, it started a very focused motion in terms of looking at our renewals. We have very specific targets. We, we like to see a renewal at 110% at the moment of renewal. And then we like to see a motion, t plus three, T plus six. That gets us to that a hundred and and 25%. But what we’ve also found out is that this needs to be an always on motion. [00:23:18] Alexandra Zagury: So one of the things that we’re doing is using this concept of precision velocity becoming very rigorous. ’cause we have all the data. Yeah. In terms of what is that next action, and really looking at starting that renewal process, we see that the partners that are able to reach the targets are the ones that start at T minus. [00:23:36] Alexandra Zagury: Six, maybe T minus three, you’re cutting it, but T minus six. And really building that constant motion, getting out in front Yeah. With the customer is really important. And then of course, we now even have these amazing go back motions, uh, with, with our partners where we actually, after the renewal, we go and. [00:23:56] Alexandra Zagury: The renewal was not at the target. We just constantly keep on going. Uh, going back with the, with the partners and we’ve unlocked a, a bevy of data. We, our operating model, we call it the pods, where the PDM sits at the center and orchestrates it with all the different roles that we have. And so we now have a very systematized moment, uh, motion of how to do the renewals. [00:24:18] Vince Menzione: So for the partners in the room, what’s one investment that they should make and what should every partner in the room do differently? Going into, uh, July 1st. [00:24:27] Alexandra Zagury: Well, I think the first thing, remember, CSP is our hero motion, so really for, uh, real, really focused on that. But the one investment, can I say two? [00:24:38] Vince Menzione: Please, please. [00:24:38] Alexandra Zagury: Your time. The, the first one is skilling, right? This is the time. [00:24:43] Vince Menzione: Yeah. [00:24:43] Alexandra Zagury: Technical intensity is super, super important, and really making those investments in skilling not only from a practice perspective, your your, your technical practice, uh, teams, but also from a sales readiness perspective. [00:24:59] Alexandra Zagury: This is a new muscle. It’s we’re all learning how to truly sell outcomes, and so getting your sales teams ready. Is is really important. And then the second one very tied to that is building your AI Center of Excellence based on the Microsoft platform. Because as we go into FY 27, you will see that the partners that prefer and grow with us are the ones that will see the investment come to them. [00:25:28] Vince Menzione: So I want to use the term front. I I, I’ve been avoiding the term frontier firm, but I think it is super critical. Everything I’ve heard today, like you need to be customer zero. You need to get in train, advance on it and go build against it. [00:25:41] Alexandra Zagury: Absolutely. Well, if you had, let me a third, I would’ve said customer zero. [00:25:46] Vince Menzione: You have it? Alright. We have less than a minute. Would you be okay if we ask for like maybe one question? Yeah, absolutely. We’ll do like one, maybe two. So good to have you by the way. Thank you, Vince. So nice to have you here. [00:26:04] Vince Menzione: I think we did such a good job. Oh, here we go. Here’s, here’s fun. A mic is coming your way. [00:26:20] Vince Menzione: Thank you. Here we go. Okay. [00:26:22] Guest: So we’ve been very keen on, um, skilling our people, and I still find it very hard to get all of the information out of Partner Center to get a complete global view. Are you and your team thinking about maybe having an MCP server access and having a real portal working with that data? [00:26:41] Alexandra Zagury: You just touched on one of our areas of improvement. Absolutely. In fact, um, thank you for, stay tuned for holding us accountable to that. That is definitely one of the things that we’re working on is how to integrate skilling hub into partner center. Right. As most of you will know, there are it Qs, and so that’s one of the things that we are definitely prioritizing, but thank you for holding me accountable to that one. [00:27:09] Vince Menzione: Awesome. [00:27:13] Vince Menzione: We have one more back here, David. I see. We wanna see how fast they can move that microphone across the room. Relay system here. The relay team. There we go. [00:27:25] Guest: That was excellent, Alexander. Thank you. And welcome. [00:27:28] Alexandra Zagury: Thank you. [00:27:29] Guest: Can you point to a specific example? ’cause I think it’s so critical what you highlighted just the skill piece and the customer outcomes piece. [00:27:35] Guest: Right. Can you point to a specific example of a story that you really love that highlights, uh, customers lighting it up with ROI. [00:27:44] Alexandra Zagury: Yeah, I think, you know, we’re, we’re, we’re a platform, so I just saw a win wire. Like at Microsoft, we get these win wires all the time about how an SSB actually won a, a deal against one of these big AI only companies. [00:28:00] Alexandra Zagury: And it was really about selling the full platform, right? Yeah. Because if, if you, if you put a full platform against an LLM proposition, I mean, the full platform really stacks up because it’s completely integrated. It’s not behemoth to one, you’re not making a bet on one company. And it really highlighted our mantra around trust and intelligence. [00:28:24] Alexandra Zagury: The customer was able to see, they, they were an M 365 customer, so all their iq, all their intelligence was already there. They knew that they, there were guardrails against it. They had a problem with shadow ai and by actually standardizing on copilot and going on that journey from copilot paid to agents, they sue the, they saw the full, uh, value proposition. [00:28:49] Alexandra Zagury: And so we won that deal and it was one of the. First E seven deals that we won, so it was great. [00:28:55] Vince Menzione: Fantastic. Great. Congratulations. [00:28:57] Alexandra Zagury: Thank you [00:28:58] Vince Menzione: Alex. I am so honored and thrilled that you got, you chose us to be your I I would say the first big Yeah, absolutely. Presentation in front of the partner community. [00:29:07] Vince Menzione: I’m so excited to have you. [00:29:08] Alexandra Zagury: Thank you [00:29:09] Vince Menzione: guys, and hopefully many more times ahead with us. [00:29:10] Alexandra Zagury: Absolutely. Invite me at anytime. [00:29:12] Vince Menzione: Okay. Well, thank you [00:29:13] Alexandra Zagury: so much. [00:29:14] Vince Menzione: Thank you. So great [00:29:15] Alexandra Zagury: to have you. Thank [00:29:16] Vince Menzione: you so much. Thanks for listening to The Ultimate Partner Podcast. If today’s conversation resonated, share it with a partner leader in your network. [00:29:26] Vince Menzione: Subscribe where you listen, and head over to the ultimate partner.com. For show notes related content and the resources for this episode. And if you haven’t already, now’s the time to register for the Ultimate Partner Live Event in Reston, Virginia, October 26th through October 28th. Until next time, keep showing up in the rooms that matter because being in the room changes everything.

Wall Street giants are partnering with Nvidia on a $500bn AI financing deal, the mega-merger between AstraZeneca and Bristol Myers Squibb has been put on ice, and queues at some EU airports have doubled because of border checks. Plus, the FT's Malaika Kanaaneh Tapper explains why Morocco's economy isn't helping its young workers. Mentioned in this podcast:Wall Street giants partner with Nvidia on $500bn AI financing dealHow AstraZeneca's pursuit of US rival Bristol Myers unravelledEU airport queues double due to border checks Hotel prices in Europe surge ahead of historic eclipseSpain's migrant amnesty a ‘very bad idea', says Swedish PMMorocco's two-speed economy leaves young workers behindWant to get in touch? Email us at podcasts@ft.comFT subscription finder: https://find-your-subscription.ft.com/?segmentId=288f5dc5-4a4b-0745-84da-8f07c7202cd4 Note: The FT does not use generative AI to voice its podcasts The FT News Briefing is produced by Victoria Craig, Sonja Hutson, Saffeya Ahmed, and Katya Kumkova. Our editor is Marc Filippino. Our show is mixed by Sam Giovinco and Alex Higgins. Additional help from Gavin Kallmann, Michael Lello, Peter Barber and David da Silva. Our executive producer is Topher Forhecz. Flo Phillips is the FT's global head of audio. The show's theme music is by Metaphor Music.Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

Plus: AstraZeneca and Bristol Myers Squibb shares swing on reports of a potential tie up. And Nissan reports its first quarterly profit in two years. Imani Moise hosts. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.